

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

OPIC  
OFFICE DE LA PROPRIÉTÉ  
INTELLECTUELLE DU CANADA



CIPO  
CANADIAN INTELLECTUAL  
PROPERTY OFFICE

Ottawa Hull K1A 0C9

(21) (A1)	2,157,596
(86)	1994/03/09
(43)	1994/09/29

(51) Int.Cl. <sup>6</sup> C12N 15/29; C12N 5/10; C12N 5/08; C07K 16/16; C  
14/415; C07K 14/725; A61K 39/35; G01N 33/564

(19) (CA) APPLICATION FOR CANADIAN PATENT (12)

(54) T Cell Epitopes of Ryegrass Pollen Allergen

(72) Griffith, Irwin J. - U.S.A. ;  
Kuo, Mei-Chang - U.S.A. ;  
Luqman, Mohammad - U.S.A. ;  
Powers, Stephen Palmer - U.S.A. ;

(71) Immulogic Pharmaceutical Corporation - U.S.A. ;

(30) (US) 08/031,001 1993/03/12

(57) 71 Claims

Notice: This application is as filed and may therefore contain an incomplete specification.



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>C07K 7/08, 15/10, 15/28</b> <b>C12N 15/29, 15/70, 1/21, A61K 37/02</b>		A3	(11) International Publication Number: <b>WO 94/21675</b> (43) International Publication Date: 29 September 1994 (29.09.94)
(21) International Application Number: <b>PCT/US94/02537</b> (22) International Filing Date: 9 March 1994 (09.03.94) (30) Priority Data: 08/031,001 12 March 1993 (12.03.93) US (71) Applicant: <b>IMMULOGIC PHARMACEUTICAL CORPORATION [US/US]; 610 Lincoln Street, Waltham, MA 02154 (US).</b> (72) Inventors: <b>GRIFFITH, Irwin, J.; 13 Southwick Road, North Reading, MA 01864 (US). KUO, Mei-chang; 5 Cox Road, Winchester, MA 01890 (US). LUQMAN, Mohammad; 13 Carriage Drive, Acton, MA 01720 (US). POWERS, Stephen, Palmer; 2008 Stearns Hill Road, Waltham, MA 02154 (US).</b> (74) Agents: <b>CHANNING, Stacey, L. et al.; Immulogic Pharmaceutical Corporation, 610 Lincoln Street, Waltham, MA 02154 (US).</b>			(81) Designated States: <b>AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 10 November 1994 (10.11.94)

**2157596**(54) Title: **T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN**

## (57) Abstract

The present invention provides isolated peptides of *Lol p I*, a major protein allergen of the species *Lolium perenne*. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of *Lol p I*. The invention also provides modified peptides having similar or enhanced therapeutic or diagnostic properties as the corresponding, naturally-occurring allergen or portion thereof, but having additional properties, e.g., reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment and diagnosis of sensitivity to *Lol p I* or an allergen immunologically related to *Lol p I* in an individual (such as *Dac g I*, *Poa p I*, or *Phl p I*) also are provided. Compositions for therapeutic, diagnostic or reagent uses comprising one or more peptides of the invention are also provided.

2157596

Claims

1. An isolated peptide of *Lol p I* or an isolated portion thereof, said peptide or portion thereof comprising at least one T cell epitope of *Lol p I*, said peptide  
5 comprising an amino acid sequence selected from the group consisting of: LPI-1 (SEQ ID NO: 4).1, LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8), LPI-8 (SEQ ID NO: 12), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-13 (SEQ ID NO: 19), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ  
10 ID NO: 25), LPI-19 (SEQ ID NO: 26), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30), all as shown in Fig. 2.
2. An isolated peptide of *Lol p I* or an isolated portion thereof, said peptide or portion thereof comprising at least one T cell epitope of *Lol p I*, said peptide  
15 having an amino acid sequence selected from the group consisting of: LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8  
20 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50), all as shown in Fig. 4.
- 25 3. An isolated peptide or portion thereof according to claim 1, wherein said portion of a peptide has a mean T cell stimulation index approximately equivalent to or greater than the mean T cell stimulation index of the corresponding peptide shown in Fig. 3.
- 30 4. An isolated peptide or portion thereof of claim 1 or 2 which comprises at least two T cell epitopes.
5. An isolated peptide or portion thereof of claim 1 or 2 which induces T cell nonresponsiveness or modifies the lymphokine secretion profile of appropriate T  
35 cell subpopulations.



6. An isolated peptide or portion thereof of claim 1 or 2 which, when administered to an individual sensitive to an allergen of the family, Poacea induces T cell anergy or modifies the lymphokine secretion profile of appropriate T cell populations.
- 5 7. A portion of an isolated peptide of claim 1 or 2 which has a mean T cell stimulation index of at least 3.5.
8. An isolated peptide or a portion thereof of claim 1 or 2 which does not  
10 bind immunoglobulin E specific for *Lol p I* in a substantial percentage of individuals sensitive to *Lol p I*, or if binding of the peptide or portion thereof to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to *Lol p I*.
- 15 9. An isolated peptide of claim 1 or 2 which binds immunoglobulin E to a substantially lesser extent than purified native *Lol p I* binds immunoglobulin E.
10. An isolated peptide or portion thereof of claim 1 or 2 which, when  
20 administered to an individual sensitive to *Lol p I* allergen, modifies the allergic response of the individual to ryegrass pollen allergen.
11. An isolated peptide or portion thereof of claim 1 or 2 which, when  
25 administered to an individual sensitive to an allergen of the family Poacea, modifies the allergic response of the individual to said allergen.
12. A portion of an isolated peptide of claim 1 or 2 wherein said portion comprises at least 15 amino acid residues.
- 30 13. An isolated nucleic acid having a sequence encoding all or a portion of a peptide of claim 1 or 2.
14. A functional equivalent of a nucleic acid sequence encoding all or a  
35 portion of a peptide of claim 1 or 2.

2157596

15. An isolated peptide that is immunologically cross-reactive with T cells reactive with a peptide of claim 1 or 2.
16. An isolated peptide or portion thereof of *Lol p I*, said peptide or portion thereof comprising at least one T cell epitope of *Lol p I*, said peptide having a positivity index of at least about 100 and mean T cell stimulation index of at least about 3.0 determined in a population of individuals sensitive to said protein allergen.
17. An isolated peptide or portion thereof of claim 16 wherein said population of individuals is at least thirty individuals.
18. An isolated peptide or portion thereof of claim 17 wherein said population of individuals is at least thirty-five individuals.
19. An isolated peptide or portion thereof of claim 17 wherein said mean T cell stimulation index is at least about 4.0.
20. An isolated peptide or portion thereof of claim 17 wherein said mean T cell stimulation index is at least about 6.0.
21. A peptide or portion thereof of claim 17 wherein said peptide is selected from the group consisting of: LPI-2 (SEQ ID NO: 5), LPI-11 (SEQ ID NO: 15), LPI-13 (SEQ ID NO: 19), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30).
22. An isolated peptide of *Lol p I*, or a portion thereof wherein said peptide is selected from the group consisting of: LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8), LPI-8 (SEQ ID NO: 12), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-13 (SEQ ID NO: 19), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-19 (SEQ ID NO: 26), LPI-22 (SEQ ID NO: 29), LPI-23 (SEQ ID NO: 30), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-

18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50) or portion thereof.

5

23. A modified peptide or a modified portion of a peptide of claim 22.

24. A modified peptide of claim 23 wherein said peptide is selected from the group consisting of: LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32),  
10 LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), and LPI-16.10 (SEQ ID NO: 38), all as shown in Fig. 4.

25. A modified peptide or a modified portion of a peptide of claim 23 or 24  
15 which does not bind immunoglobulin E specific for *Lol p I* in a substantial percentage of individuals sensitive to *Lol p I*, or if binding of the peptide or portion thereof to said immunoglobulin E occurs, such binding does not result in release of mediators from mast cells or basophils in a substantial percentage of individuals sensitive to *Lol p I*.

20

26. A modified peptide or a modified portion of a peptide of claim 23 or 24 which modifies, in an individual sensitive to *Lol p I* or an immunologically related allergen, the allergic response of the individual to *Lol p I* allergen or said related allergen.

25

27. An isolated peptide comprising at least two regions, each region comprising at least one T cell epitope of *Lol p I*, said regions each comprising all or a portion of an amino acid sequence selected from the group consisting of:  
30 LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8), LPI-8 (SEQ ID NO: 12), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-13 (SEQ ID NO: 19), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), LPI-23 (SEQ ID NO: 30), LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32),  
35 LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35)

NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10  
(SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-  
18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43),  
LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID  
5 NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2  
(SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50).

28. An isolated peptide of claim 27 wherein said regions comprise an amino  
acid sequence selected from the group consisting of: LPI-3 (SEQ ID NO: 6),  
10 LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15),  
LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID  
NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), LPI-23 (SEQ ID  
NO: 30), LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4  
(SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-  
15 16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID  
NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7  
(SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-  
20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46),  
LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID  
20 NO: 49), and LPI-23.4 (SEQ ID NO: 50), or a portion thereof containing at least  
two *Lol p I* epitopes.

29. An isolated peptide of *Lol p I*, wherein said peptide comprises a  
combination of regions selected from the group consisting of:  
25 LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14),  
LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID  
NO: 22), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ  
ID NO: 29), and LPI-23 (SEQ ID NO: 30);  
LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14),  
30 and LPI-11 (SEQ ID NO: 15);  
LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14),  
LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16 (SEQ ID  
NO: 22);

LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16.1 (SEQ ID NO: 23);

5 LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16.1 (SEQ ID NO: 23);

LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), and LPI-20 (SEQ ID NO: 27);

10 LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30);

LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), and LPI-20 (SEQ ID NO: 27);

15 LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);

---

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);

20 LPI-18 (SEQ ID NO: 25) and LPI-20 (SEQ ID NO: 27);

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27) and LPI-23 (SEQ ID NO: 30);

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27) and LPI-16.1 (SEQ ID NO: 23);

25 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30) and LPI-16.1 (SEQ ID NO: 23);

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23) and LPI-11 (SEQ ID NO: 15);

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23) and LPI-4.1 (SEQ ID NO: 8);

30 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16 (SEQ ID NO: 23).1, LPI-4.1 (SEQ ID NO: 8) and LPI-22 (SEQ ID NO: 29);

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-11 (SEQ ID NO: 15) and LPI-4.1 (SEQ ID NO: 8);

35

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-11 (SEQ ID NO: 15), LPI-4.1 (SEQ ID NO: 8) and LPI-22 (SEQ ID NO: 29);

5 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-16.1 (SEQ ID NO: 23), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30); and

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-16.1 (SEQ ID NO: 23) and LPI-22 (SEQ ID NO: 29).

10

30. An isolated peptide of *Lol p I*, wherein said peptide comprises a combination of regions selected from the group consisting of:

LPI-16.2 (SEQ ID NO: 31), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);

15 LPI-16.3 (SEQ ID NO: 32), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);

LPI-16.4 (SEQ ID NO: 33), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);

20 LPI-16.5 (SEQ ID NO: 34), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);

LPI-16.6 (SEQ ID NO: 35), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);

LPI-16.7 (SEQ ID NO: 36), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);

25 LPI-16.9 (SEQ ID NO: 37), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30); and

LPI-16.10 (SEQ ID NO: 38), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30).

30 31. A monoclonal antibody, polyclonal antibody, or immunoreactive fragment thereof specifically reactive with a peptide of claim 1 or 2.

32. An isolated peptide produced in a host cell transformed with the nucleic acid of claim 13.

35

33. An isolated peptide produced in a host cell transformed with the nucleic acid of claim 14.
34. An isolated nucleic acid having a sequence encoding a peptide of claim 27  
5 or 29.
35. The functional equivalent of an isolated nucleic acid sequence encoding a peptide of claim 27 or 29.
- 10 36. An isolated peptide produced in a host cell transformed with the nucleic acid of claim 34.
37. An expression vector comprising a nucleic acid sequence coding for a peptide of claim 1 or 2.
- 15 38. ~~An expression vector comprising the functional equivalent of a sequence coding for a peptide of claim 1 or 2.~~
39. An expression vector comprising a nucleic acid sequence coding for a  
20 peptide of claim 27 or 29.
40. An expression vector comprising the functional equivalent of a nucleic acid sequence coding for a peptide of claim 27 or 29.
- 25 41. All or a portion of an isolated peptide of *Lol p I*, said peptide or portion thereof comprising at least one T cell epitope of said protein allergen, said peptide having the formula  $X_n-Y-Z_m$ , wherein Y is an amino acid sequence selected from the group consisting of: LPI-1 (SEQ ID NO: 3), LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ  
30 ID NO: 8), LPI-5 (SEQ ID NO: 9), LPI-6 (SEQ ID NO: 10), LPI-7 (SEQ ID NO: 11), LPI-8 (SEQ ID NO: 12), LPI-9 (SEQ ID NO: 13), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-12 (SEQ ID NO: 17), LPI-13 (SEQ ID NO: 19), LPI-14 (SEQ ID NO: 20), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-17 (SEQ ID NO: 24), LPI-18 (SEQ  
35 ID NO: 25), LPI-19 (SEQ ID NO: 26), LPI-21 (SEQ ID NO: 28), LPI-22 (SEQ

2157596

International Application No.: PCT/US94/02537

International Filing Date: 09/03/94

LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50) wherein  $X_n$  are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of said protein allergen, wherein  $Z_m$  are amino acid residues contiguous to the carboxy terminus of Y in the amino acid sequence of said protein allergen, wherein n is 0-30 and wherein m is 0-30.

42. A portion of an isolated peptide of claim 40 wherein the portion comprises at least fifteen amino acid residues.

43. A composition comprising at least one isolated peptide or a portion thereof of claim 1 or 2 and a pharmaceutically acceptable carrier or diluent.

44. A composition comprising at least one isolated peptide or portion thereof of claim 23 or 24 and a pharmaceutically acceptable carrier or diluent.

45. A therapeutic composition comprising an isolated peptide or portion thereof of claim 27 or 29 and a pharmaceutically acceptable carrier or diluent.

46. Use of a composition of claim 43 in the manufacture of a medicament for treating sensitivity to *Lol p I* protein allergen or an allergen which is immunologically cross reactive with *Lol p I* protein allergen.

47. Use of a composition of claim 44 in the manufacture of a medicament for treating sensitivity to *Lol p I* protein allergen or an allergen which is immunologically cross reactive with *Lol p I* protein allergen.

48. Use of at least two compositions of claim 43 in the manufacture of a medicament for treating sensitivity to *Lol p I* protein allergen or an allergen which is immunologically cross reactive with *Lol p I* protein allergen.

49. The use of the composition of claim 46 in the manufacture of a medicament for treating sensitivity to *Lol p I* protein allergen, wherein said immunologically cross reactive allergen is *Dac g I*, *Poa p I* or *Phl p I*.

50. A method of detecting sensitivity to *Lol p I* protein allergen or an immunologically cross reactive allergen in an individual, comprising combining a blood sample obtained from the individual with at least one peptide of claim 1 or 2, *in vitro*, under conditions appropriate for binding of



2157596

International Application No.: PCT/US94/02537

International Filing Date: 09/03/94

blood components with the peptide, and determining the extent to which such binding occurs as indicative of sensitivity in the individual to ryegrass pollen allergen or said immunologically cross-reactive allergen.

51. A method of claim 50 wherein the extent to which binding occurs is determined by assessing T cell function, T cell proliferation or a combination thereof.

52. A composition comprising a pharmaceutically acceptable carrier or diluent and at least two peptides, selected from the group consisting of: LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8), LPI-8 (SEQ ID NO: 12), LPI-11 (SEQ ID NO: 15), LPI-13 (SEQ ID NO: 19), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), LPI-23 (SEQ ID

NO: 30), LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50) and wherein said composition comprises a sufficient percentage of the T cell epitopes of said protein allergen such that T cells of an individual sensitive to *Lol p I* protein pollen or an immunologically cross reactive allergen, are tolerized to said at least one protein allergen.

53. A composition of claim 45 comprising a combination of peptides selected from the group consisting of:

LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);  
LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), and LPI-11 (SEQ ID NO: 15);

2157596

LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23) and LPI-11 (SEQ ID NO: 15);  
 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23) and LPI-4.1 (SEQ ID NO: 8);  
 5 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-4.1 (SEQ ID NO: 8) and LPI-22 (SEQ ID NO: 29);  
 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-11 (SEQ ID NO: 15) and LPI-4.1 (SEQ ID NO: 8);  
 10 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-11 (SEQ ID NO: 15), LPI-4.1 (SEQ ID NO: 8) and LPI-22 (SEQ ID NO: 29);  
 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);  
 15 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-16.1 (SEQ ID NO: 23), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30); and  
 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-16.1 (SEQ ID NO: 23) and LPI-22 (SEQ ID NO: 29).

20

54. A composition of claim 43 comprising a combination of peptides selected from the group consisting of:

LPI-16.2 (SEQ ID NO: 31), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 25 LPI-16.3 (SEQ ID NO: 32), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 LPI-16.4 (SEQ ID NO: 33), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 LPI-16.5 (SEQ ID NO: 34), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 30 LPI-16.6 (SEQ ID NO: 35), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 LPI-16.7 (SEQ ID NO: 36), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);

LPI-16.9 (SEQ ID NO: 37), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30); and  
LPI-16.10 (SEQ ID NO: 38), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30).

5

55. Use of composition of claim 52, 53 or 54 in the manufacture of a medicament for use in treating sensitivity to *Lol p I* allergen or an immunologically cross-reactive allergen.

10

56. A method of designing antigenic fragments of *Lol p I*, which when administered to ryegrass pollen sensitive individuals in sufficient quantity will modify the individual's allergic reaction to ryegrass pollen comprising the steps of:

15

- (a) recombinantly or synthetically producing peptides of *Lol p I*;
- (b) examining said peptides for their ability to influence B cell and/or T cell responses in ryegrass pollen sensitive individuals;
- (c) selecting appropriate peptides which contain epitopes recognized by the cells, and
- (d) combining epitope-containing regions to include multiple epitopes in one peptide.

20

57. A method of designing antigenic fragments of *Lol p I*, which when administered to ryegrass pollen sensitive individuals in sufficient quantity will modify the individual's allergic reaction to ryegrass pollen comprising the steps of:

25

- (a) recombinantly or synthetically producing peptides of *Lol p I*;
- (b) examining said peptides for their ability to influence B cell and/or T cell responses in ryegrass pollen sensitive individuals; and
- (c) selecting appropriate peptides which contain epitopes recognized by the cells.

30

58. A T cell capable of recognizing a peptide of claim 1 or 2.

59. A receptor of a T cell capable of recognizing a peptide of claim 1 or 2.

35

60. An isolated nucleic acid having a nucleotide sequence coding for *Dac g I*, or the functional equivalent of said nucleotide sequence.

215759 6

61. An isolated nucleic acid sequence of claim 60 wherein said nucleotide sequence comprises the nucleotide sequence of Fig. 5.
- 5 62. An expression vector comprising a nucleotide sequence coding for *Dac g I*, or the functional equivalent of said nucleotide sequence.
63. A host cell transformed to express a protein encoded by the nucleic acid of claim 60.
- 10 64. Isolated *Dac g I* protein produced in a host cell transformed with the nucleic acid of claim 60.
- 15 65. An isolated nucleic acid having a nucleotide sequence coding for *Poa p I*, or the functional equivalent of said nucleotide sequence.
- 
66. An isolated nucleic acid sequence of claim 65 wherein said nucleotide sequence comprises the nucleotide sequence of Fig. 6.
- 20 67. An expression vector comprising a nucleotide sequence coding for *Poa p I*, or the functional equivalent of said nucleotide sequence.
68. A host cell transformed to express a protein encoded by the nucleic acid of claim 65.
- 25 69. Isolated *Poa p I* protein produced in a host cell transformed with the nucleic acid of claim 60.
70. An isolated protein allergen that is immunologically related to *Lol p I*.
- 30 71. An isolated protein allergen of claim 70 wherein said protein allergen is *Dac g I* or *Poa p I*.

## T CELL EPITOPES OF RYEGRASS POLLEN ALLERGEN

### Background of the Invention

5       The most abundant proteins of grass pollen are allergens, which are the major cause of allergic disease in temperate climates (Marsh (1975), "Allergens and the genetics of allergy"; in M. Sela (ed), *The Antigens*, 3:271-359, Academic Press Inc., London, New York)., Hill *et al.* (1979) *Medical Journal of Australia*, 1:426-429). The first descriptions of the allergenic proteins in ryegrass showed that they are  
10 immunochemically distinct, and are known as groups I, II, III and IV (Johnson and Marsh (1965), *Nature*, 206:935-942; and Johnson and Marsh (1966) *Immunochemistry*, 3:91-100). Using the International Union of Immunological Societies' (IUIS) nomenclature, these allergens are designated *Lol p I*, *Lol p II*, *Lol p III*, and *Lol p IV*. Another important *Lolium perenne* allergen which has been  
15 identified in the literature is *Lol p IX*, also known as *Lol p V* or *Lol p Ib*, which has been found to be closely related to the Group V protein allergens in grasses.

These proteins have been identified in pollen from ryegrass, *Lolium perenne*, and act as antigens in triggering immediate (Type 1) hypersensitivity in susceptible humans.

20 ~~*Lol p I* is defined as an allergen because of its ability to bind to specific IgE in sera of ryegrass-sensitive patients, to act as an antigen in IgG responses and to trigger T-cell responses. The allergenic properties have been assessed by direct skin testing of grass pollen-sensitive patients. The results showed that 84% had a skin sensitivity to *Lol p I* (Freidhoff, et al., (1986) *J. Allergy Clin. Immunol.*, 78:1190-1201)~~  
25 demonstrating the primary importance of this protein as the major allergen. Furthermore, 95% of patients demonstrated to be grass pollen-sensitive possessed specific IgE antibody that bound to *Lol p I*, as demonstrated by immunoblotting (Ford and Baldo (1986) *International Archives of Allergy and Applied Immunology*, 81:193-203).

30 Substantial allergenic cross-reactivity between grass pollens has been demonstrated using an IgE-binding assay, the radioallergo-sorbent test (RAST), for example, as described by Marsh *et al.* (1970) *J. Allergy*, 46:107-121, and Lowenstein (1978) *Prog. Allergy*, 25:1-62. (Karger, Basel).

The immunochemical relationship of *Lol p I* with other grass pollen  
35 antigens has been demonstrated using both polyclonal and monoclonal antibodies (e.g., Smart and Knox (1979) *International Archives of Allergy and*

*Applied Immunology*, 62: 173-187; Singh and Knox (1985), *International Archives of Allergy and Applied Immunology*, 78:300-304). Antibodies have been prepared to both purified proteins and IgE-binding components. These data demonstrate that the major allergen present in pollen of closely related  
5 grasses is immunochemically similar to *Lol p I* (Singh and Knox, *supra*). Grasses that may be considered immunochemically related to *Lol p I* and that comprise allergens which may be considered immunologically cross-reactive with antibody to *Lol p I* include:

Pooid (festucoid) grasses of the Poaceae (Gramineae) family include the  
10 following. GROUP 1: Triticaneae: *Bromus inermis*, smooth brome; *Agropyron repens*, English couch; *A. cristatum*; *Secale cereale* rye *Triticum aestivum*, wheat. GROUP 2: Poanae: *Dactylis glomerata*, orchard grass of cocksfoot; *Festuca elatior*, meadow fescue; *Lolium perenne*, perennial ryegrass; *L. multiflorum*, Italian ryegrass; *Poa pratensis*, Kentucky bluegrass;  
15 *P. compressa*, flattened meadow grass; *Avena sativa*, oat; *Holcus lanatus*, velvet grass or Yorkshire fog; *Anthoxanthum odoratum*; sweet vernal grass; *Arrhenatherum elatius*, oat grass; *Agrostis alba*, red top; *Phleum pratense*, timothy; *Phalaris arundinacea*, reed canary grass. *Panicoid* grass, *Paspalum notatum*, Bahia grass, ~~Andropogonoid grasses: *Sorghum halepensis*, Johnson~~  
20 grass.

In view of the prevalence of ryegrass pollen allergens and related grass allergens all over the world, there is a pressing need for the development of compositions and methods that could be used in detecting sensitivities to *Lol p I* or other immunologically related grass allergens, or in treating sensitivities to  
25 such allergens, or in assisting in the manufacture of medicaments to treat such sensitivities. The present invention provides materials and methods having one or more of those utilities.

#### Summary of the Invention

30 The present invention provides isolated peptides of *Lol p I*. Peptides within the scope of the invention comprise at least one T cell epitope, preferably at least two T cell epitopes of *Lol p I*. The invention further provides peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p I*.

The invention also provides modified peptides having similar or enhanced therapeutic or diagnostic properties as the corresponding, naturally-occurring allergen or portion thereof, but also having advantageous physical or biological properties, such as reduced side effects, reduced IgE binding, improved solubility, increased *in vitro* or *in vivo* T cell stimulating ability, increased stability or the like. Preferred peptides of the invention are capable of modifying, in a *Lol p I*-sensitive individual to whom they are administered, the allergic response of the individual to *Lol p I* or an allergen immunologically cross-reactive with *Lol p I*, e.g., allergens derived from pollen belonging to the Poaceae (Gramineae) family, such as *Dactylis glomerata* (*Dac g I*), *Poa pretensis* (*Poa p I*) and *Phleum pratense* (*Phl p I*), as discussed above.

The present invention also provides non-native (i.e., recombinant or chemically synthesized) *Lol p I* peptides or their derivatives or homologues and provides non-native allergenic protein or peptides immunologically cross-reactive with antibodies or with T cells of *Lol p I* or derivatives or homologues thereof.

The present invention also provides *Dac g I* and *Poa p I* protein allergens which are immunologically cross-reactive with *Lol p I*, and fragments of *Dac g I* and *Poa p I* produced in a host cell transformed with a nucleic acid sequence coding for *Dac g I* and *Poa p I*, respectively, and fragments of *Dac g I* and *Poa p I* prepared synthetically. The present invention further provides nucleic acid sequences coding for *Dac g I*, *Poa p I* and fragments thereof. Also provided are isolated peptides of *Dac g I* and *Poa p I* comprising at least one T cell epitope which are immunologically cross-reactive with peptides comprising at least one T cell epitope derived from *Lol p I*.

Methods of treatment and of diagnosis of sensitivity to ryegrass pollen protein, *Lol p I*, or to pollen proteins that are immunologically related to *Lol p I* (such as *Dac g I*, *Phl p I* and *Poa p I*), as well as compositions comprising one or more peptides of the invention, are also provided.

Further features of the present invention will be better understood from the following detailed description of the preferred embodiments of the invention in conjunction with the appended figures.

#### Brief Description of the Figures

2157596

Fig. 1 shows the nucleotide sequence of cDNA clone 26.j (SEQ ID NO 1) and its predicted amino acid sequence (SEQ ID NO: 2). Clone 26.j is a PCR-generated, full-length clone of *Lol p I*.

Fig. 2 shows various peptides of desired lengths derived from *Lol p I* (SEQ ID NO: 3-30); such peptides include polymorphisms inherent in the *Lol p I* sequence (i.e., LPI-4.1 (SEQ ID NO: 8) and LPI-16.1 (SEQ ID NO: 23)) or homologues of peptides derived from *Lol p I* (i.e., LPI-11 (SEQ ID NO: 15), and LPI-12 (SEQ ID NO: 17)).

Fig. 3 is a graphic representation depicting responses of T cell lines from thirty-five grass-sensitive patients primed *in vitro* with purified native *Lol p I* and analyzed for response to various *Lol p I* peptides by percent of positive responses (with an S.I. of at least two, shown over each bar), the mean stimulation index of positive response for the peptide (shown over each bar in parentheses) and the positivity index (% positive x mean S.I. index, Y axis).

Fig. 4 shows various peptides of desired lengths derived from *Lol p I* (SEQ ID NO: 23, 25, 27, 30-50).

Fig. 5 shows the nucleotide sequence of cDNA clone 106.5 (SEQ ID NO: 51) and its predicted amino acid sequence (SEQ ID NO: 52). Clone 106.5 is a PCR-generated, full-length clone of *Dac g I*.

Fig. 6 shows the nucleotide sequence of cDNA clone 114 (SEQ ID NO: 53) and its predicted amino acid sequence (SEQ ID NO: 54). Clone 114 is a PCR-generated, full-length clone of *Poa p I*.

Fig. 7 shows the nucleotide sequence of cDNA clone 20 (SEQ ID NO: 55) and its predicted amino acid sequence (SEQ ID NO: 56). Clone 20 is a PCR generated, full length clone of *Phl p I*.

Fig. 8 shows a comparison of the amino acid sequences of the mature protein of *Lol p I* (SEQ ID NO: 57), *Dac g I* (SEQ ID NO: 58), *Phl p I* (SEQ ID NO: 59), and *Poa p I* (SEQ ID NO: 60), including polymorphisms thereof.

Fig. 9 shows a comparison of various peptides comprising at least one T cell epitope derived from *Lol p I*, with homologous peptides derived from the same regions of *Dac g I*, *Phl p I*, and *Poa p I* (SEQ ID NO: 23, 25, 27, 30, 61-70).

#### Detailed Description of the Invention

The present invention provides isolated peptides derived from *Lol p I* (SEQ ID NO: 3-50). The present invention also provides *Dac g I* and *Poa p I* protein allergens which are immunologically cross-reactive with *Lol p I*. The term "peptide"



as used herein refers to any protein fragment of *Lol p I* that induces an immune response. The terms "fragment" and "antigenic fragment" of a protein as used interchangeably herein refer to an amino acid sequence having fewer amino acid residues than the entire native amino acid sequence of the protein from which the fragment is derived, and that induces an immune response. The terms "isolated" and "purified" as used herein refer to peptides of the invention which are substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or substantially free of chemical precursors or other chemicals when synthesized chemically. Preferred peptides of the invention include peptides derived from *Lol p I* which comprise at least one T cell epitope of the allergen, or a portion of such a peptide which includes at least one T cell epitope.

Peptides comprising at least two regions, each region comprising at least one T cell epitope *Lol p I* are also within the scope of the invention. Isolated peptides or regions of isolated peptides, each comprising at least two T cell epitopes of the *Lol p I* protein allergen are particularly desirable for increased therapeutic effectiveness. Peptides that are immunologically related (e.g., by antibody or T cell cross-reactivity) to peptides of the present invention, such as peptides derived from *Dac g I* and *Poa p I*, are also within the scope of the invention. Peptides immunologically related by antibody cross-reactivity are recognized by antibodies specific for a peptide of *Lol p I*.

Peptides immunologically related to a given peptide by T cell cross-reactivity are capable of also reacting with the same T cells that react with that given peptide.

Isolated protein and peptides of the invention can be produced by recombinant DNA techniques in a host cell transformed with a nucleic acid having a sequence encoding such peptide. The isolated peptides of the invention can also be produced by chemical synthesis. When a protein or peptide is produced by recombinant techniques, host cells transformed with a nucleic acid having a sequence encoding a peptide of the invention or the functional equivalent of the nucleic acid sequence are cultured in a medium suitable for the cells. Peptides can be purified from cell culture medium, host cells, or both, using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis or immunopurification with antibodies specific for the peptide, the protein allergen from which the peptide is derived, or a portion thereof.

The present invention provides expression vectors and host cells transformed to express the nucleic acid sequences of the invention. Nucleic acids coding for *Lol p I* peptides of the invention, or at least a portion thereof, may be expressed in bacterial

cells such as *E. coli*, insect cells, yeast, or mammalian cells such as Chinese hamster ovary cells (CHO). Suitable expression vectors, promoters, enhancers, and other expression control elements may be found in Sambrook et al. *Molecular Cloning: A Laboratory Manual*, second edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Other suitable expression vectors, promoters, enhancers, and other expression elements are known to those skilled in the art. Expression in mammalian, yeast or insect cells leads to partial or complete glycosylation of the recombinant material and formation of any inter- or intra-chain disulfide bonds. Suitable vectors for expression in yeast include YepSec1 (Baldari et al. (1987) *Embo J.*, 6: 229-234); pMFa (Kurjan and Herskowitz (1982) *Cell*, 30: 933-943); JRY88 (Schultz et al. (1987) *Gene*, 54: 113-123) and pYES2 (Invitrogen Corporation, San Diego, CA). These vectors are freely available. Baculovirus and mammalian expression systems are also available. For example, a baculovirus system is commercially available (PharMingen, San Diego, CA) for expression in insect cells while the pMSG vector is commercially available (Pharmacia, Piscataway, NJ) for expression in mammalian cells.

For expression in *E. coli*, suitable expression vectors include, among others, pTRC (Amann et al. (1988) *Gene*, 69: 301-315); pGEX (Amrad Corp., Melbourne, Australia); pMAL (N.E. Biolabs, Beverly, MA); pRIT5 (Pharmacia, Piscataway, NJ); pET-11d (Novagen, Madison, WI) Jameel et al., (1990) *J. Virol.*, 64:3963-3966; and pSEM (Knapp et al. (1990) *BioTechniques*, 8: 280-281). The use of pTRC, and pET-11d, for example, will lead to the expression of unfused protein. The use of pMAL, pRIT5 pSEM and pGEX will lead to the expression of allergen fused to maltose E binding protein (pMAL), protein A (pRIT5), truncated  $\beta$ -galactosidase (PSEM), or glutathione S-transferase (pGEX). When a *Lol p I* peptide of the invention, is expressed as a fusion protein, it is particularly advantageous to introduce an enzymatic cleavage site at the fusion junction between the carrier protein and the *Lol p I* peptide. The *Lol p I* peptide may then be recovered from the fusion protein through enzymatic cleavage at the enzymatic site and biochemical purification using conventional techniques for purification of proteins and peptides. Suitable enzymatic cleavage sites include those for blood clotting Factor Xa or thrombin for which the appropriate enzymes and protocols for cleavage are commercially available from, for example, Sigma Chemical Company, St. Louis, MO and N.E. Biolabs, Beverly, MA. The different vectors also have different promoter regions allowing constitutive or inducible expression with, for example, IPTG induction (PRTC, Amann et al., (1988)

*supra*; pET-11d, Novagen, Madison, WI) or temperature induction (pRIT5, Pharmacia, Piscataway, NJ). It may also be appropriate to express recombinant *Lol p I* peptides in different *E. coli* hosts that have an altered capacity to degrade recombinantly expressed proteins (e.g., U.S. Patent 4,758,512). Alternatively, it may be advantageous to alter the nucleic acid sequence to use codons preferentially utilized by *E. coli*, where such nucleic acid alteration would not affect the amino acid sequence of the expressed protein.

Host cells can be transformed to express the nucleic acid sequences of the invention using conventional techniques such as calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, or electroporation. Suitable methods for transforming the host cells may be found in Sambrook et al. *supra*, and other laboratory textbooks. The nucleic acid sequences of the invention may also be chemically synthesized using standard techniques (i.e., solid phase synthesis). Details of the cloning of *Lol p I* are given in the Examples.

Inducible non-fusion expression vectors include pTrc (Amann *et al.*, (1988) *Gene*, 69:301-315) and pET11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California (1990), 185:60-89). While target gene expression relies on host RNA polymerase transcription from the hybrid *trp-lac* fusion promoter in pTrc, expression of target genes inserted into

pET11d relies on transcription from the T7 *gn10-lac O* fusion promoter mediated by coexpressed viral RNA polymerase (T7 *gn1*). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident  $\lambda$  prophage harboring a T7 *gn1* under the transcriptional control of the *lacUV 5* promoter.

One strategy to maximize recombinant *Lol p I* peptide expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology*, Academic Press, San Diego, California (1990), 185:119-128). Another strategy would be to alter the nucleic acid sequence of the desired gene to be inserted into an expression vector so that the individual codons for each amino acid would be those preferentially utilized in highly expressed *E. coli* proteins (Wada *et al.*, (1992) *Nuc. Acids Res.*, 20:2111-2118). Such alteration of nucleic acid sequences of the invention could be carried out by standard DNA synthesis techniques.

The nucleic acids of the invention can also be chemically synthesized using standard techniques. Various methods of chemically synthesizing

2157596

polydeoxynucleotides are known, including solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura *et al.* U.S. Patent 4,598,049; Caruthers *et al.* U.S. Patent 4,458,066; and Itakura U.S. Patents 4,401,796 and 4,373,071, incorporated by reference herein).

5       The present invention also provides fragments of nucleic acid sequences encoding peptides of the invention. As used herein, the term "fragment" of a nucleic acid sequence refers to a nucleotide sequence having fewer bases than the nucleotide sequence coding for the entire amino acid sequence of the protein. Nucleic acid sequences used in any embodiment of this invention can be cDNA obtained as  
10       described herein, or alternatively, can be any oligodeoxynucleotide sequence having all or a portion of a sequence represented herein, or their functional equivalents. Such oligodeoxynucleotide sequences can be produced chemically or mechanically, using known techniques. A functional equivalent of an oligonucleotide sequence of *Lol p I* is one which is 1) a sequence capable of hybridizing to a complementary  
15       oligonucleotide to which the sequence (or corresponding sequence portions) of *Lol p I* as shown in Fig. 1 (SEQ ID NO: 1) or fragments thereof hybridizes, or 2) the sequence (or corresponding sequence portion) complementary to the sequence of *Lol p I* as shown in Fig. 1 (SEQ ID NO: 1), and/or 3) a sequence which encodes a product (e.g., a polypeptide or peptide) having the same functional characteristics of the  
20       product encoded by the sequence (or corresponding sequence portion) of *Lol p I* as shown in Fig. 1 (SEQ ID NO: 1). Whether a functional equivalent must meet one or both criteria will depend on its use (e.g., if it is to be used only as an oligonucleotide probe, it need meet only the first or second criteria and if it is to be used to produce a *Lol p I* peptide of the invention, it need only meet the third criterion).

25       Preferred nucleic acids encode a peptide having at least about 50% homology to a *Lol p I* peptide of the invention, more preferably at least about 60% homology and most preferably at least about 70% homology with a *Lol p I* peptide of the invention. Nucleic acids that encode peptides having at least about 90%, more preferably at least about 95%, and most preferably at least about 98-99% homology with *Lol p I* peptides  
30       of the invention are also within the scope of the invention. Homology refers to sequence similarity between two peptides of *Lol p I*, or between two nucleic acid molecules. Homology can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same nucleotide or amino acid, then molecules are

homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences.

Preferred nucleic acid fragments encode peptides of at least 7 amino acid residues in length, and preferably 13-40 amino acid residues in length, and more preferably at least 16-30 amino acids residues in length. Nucleic acid fragments encoding peptides of at least 30 amino acid residues in length, at least 40 amino acid residues in length, at least about 80 amino acid residues in length, at least about 100 amino acid residues in length or more, are also contemplated.

Also within the scope of the invention are nucleic acid sequences encoding allergens immunologically cross-reactive with *Lol p I*, such as full length *Dac g I* and *Poa p I* proteins or peptides (Figs 5 (SEQ ID NO: 52), 6 (SEQ ID NO: 54), and 9 (SEQ ID NO: 23, 25, 27, 30, 61-70)). Proteins and peptides of *Dac g I* and *Poa p I* may be produced recombinantly as discussed above, or synthetically. Expression vectors and host cells transformed to express *Dac g I* and *Poa p I* proteins or peptides thereof are also within the scope of the invention. Details of the cloning of *Dac g I* and *Poa p I* are given in the examples.

The present invention also provides a method of producing isolated *Lol p I* peptides of the invention or a portion thereof, comprising the steps of culturing a host cell transformed with a nucleic acid sequence encoding a *Lol p I* peptide of the invention in an appropriate medium to produce a mixture of cells and medium containing said *Lol p I* peptide; and purifying the mixture to produce substantially pure *Lol p I* peptide. Host cells transformed with an expression vector containing DNA coding for a *Lol p I* peptide of the invention are cultured in a suitable medium for the host cell. *Lol p I* peptides of the invention can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis and immunopurification with antibodies specific for the *Lol p I* peptides or portions thereof.

Another aspect of the present invention pertains to an antibody specifically reactive with a *Lol p I* peptide. Such antibodies may be used to standardize allergen extracts or to isolate the naturally occurring *Lol p I*. Also, *Lol p I* peptides of the invention can be used as "purified" allergens to standardize allergen extracts. For example, an animal such as a mouse or rabbit can be immunized with an immunogenic form of an isolated *Lol p I* peptide of the invention capable of eliciting an antibody response. Techniques for conferring immunogenicity on a peptide include conjugation

**2157596**

to carriers or other techniques well-known in the art. The *Lol p I* peptide can be administered in the presence of adjuvant. The progress of immunization can be monitored by detection of antibody titers in plasma or serum standard ELISA or other immunoassay can be used with the immunogen as antigen to assess the levels of antibodies.

Following immunization, anti-*Lol p I* peptide antisera can be obtained and, if desired, polyclonal anti-*Lol p I* peptide antibodies from the serum. To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Hybridoma cells can be screened immunochemically for production of antibodies reactive with the *Lol p I* peptides of the invention. These sera or monoclonal antibodies can be used to standardize allergen extracts.

Through use of the peptides and antibodies of the present invention, preparations of consistent, well-defined composition and uniform biological activity can be made. Compositions having therapeutic activity may be administered for therapeutic purposes (e.g., to modify the allergic response of a ryegrass sensitive individual to pollen of such grasses or pollen of an immunologically related grass such as *Dac g I*, *Poa p I* and *Phl p I*). Administration of such peptides may, for example, modify B-cell response to *Lol p I* allergen, T-cell response to *Lol p I* allergen or both responses. Isolated peptides can also be used to study the mechanism of immunotherapy of ryegrass pollen allergy and to design modified derivatives or analogues useful in immunotherapy. Compositions according to the invention will have utility in diagnosis of ryegrass sensitivity or sensitivity to grass allergens cross-reactive to ryegrass allergens, because the components include T cell epitopes recognizing the allergens.

The present invention also pertains to T cell clones which specifically recognize *Lol p I* peptides of the invention. These T cell clones may be suitable for isolation and molecular cloning of the gene for the T cell receptor which is specifically reactive with a peptide of the present invention. The T cell clones may be produced as described in Example 4, or as described in *Cellular Molecular Immunology*, Abdul K. Abbas et al., W.B. Saunders Co. (1991) pg. 139. The present invention also pertains to soluble T cell receptors. These receptors may inhibit antigen-dependent activation of the relevant T cell subpopulation within an individual sensitive to *Lol p I*. Antibodies specifically reactive with such a T cell receptor can also be produced according to the

techniques described herein. Such antibodies may also be useful to block T-cell-MHC interaction in an individual. Methods for producing soluble T cell receptors are described in *Immunology: A Synthesis*, 2nd Ed., Edward S. Golub *et al.*, Sinaur Assoc., Sunderland, Massachusetts, (1991) pp. 366-369.

5           It is also possible to modify the structure of a peptide of the invention to achieve additional advantageous physical or biological properties such as increasing solubility, enhancing therapeutic or preventive efficacy, increasing stability (e.g., shelf life *ex vivo* or resistance to proteolytic degradation *in vivo*), decreasing adverse side effects, and the like. A modified peptide can be produced in which the amino acid  
10       sequence has been altered, such as by amino acid substitution, deletion, or addition, in order to modify immunogenicity and/or to reduce allergenicity. Peptides may also be advantageously modified by addition or conjugation with another peptide or other component.

          For example, a peptide can be modified so that it maintains the ability to induce  
15       T cell anergy and to bind MHC proteins but reduces the ability to induce a strong proliferative response, or possibly any proliferative response, when administered in immunogenic form. In this instance, critical binding residues for the T cell receptor can be determined using known techniques (e.g., substitution of each residue and  
          determination of the presence or absence of T cell reactivity). Those residues shown  
20       to be essential to interact with the T cell receptor can be modified by replacing the essential amino acid with another preferably similar amino acid residue (a "conservative substitution") whose presence is shown to enhance, diminish but not eliminate, or not affect T cell reactivity. In addition, those amino acid residues that are not essential for T cell receptor interaction can be modified by replacement with  
25       another amino acid whose incorporation may enhance, diminish or not affect T cell reactivity but does not eliminate binding to relevant MHC.

          Additionally, peptides of the invention can be modified by replacing an amino acid shown to be essential to interact with the MHC protein complex with another, preferably similar amino acid residue (conservative substitution) whose presence is  
30       shown to enhance, diminish but not eliminate or not affect T cell reactivity. In addition, amino acid residues that are not essential for interaction with the MHC protein complex but that still bind the MHC protein complex can be modified by replacement with another amino acid whose incorporation may enhance, not affect, or diminish but not eliminate T cell reactivity. Preferred amino acid substitutions for non-

essential amino acids include, but are not limited to substitutions with alanine, glutamic acid, or a methyl amino acid.

In order to enhance stability and/or reactivity, peptides of the invention can also be modified to incorporate one or more polymorphisms in the amino acid sequence of the protein allergen resulting from natural allelic variation. Additionally, D-amino acids, non-natural amino acids or non-amino acid analogues can be substituted or added to produce a modified peptide within the scope of this invention. Furthermore, peptides of the present invention can be modified using the polyethylene glycol (PEG) method of A. Schon and co-workers (Wie et al., *supra*) to produce a protein or peptide conjugated with PEG. In addition, PEG can be added during chemical synthesis of a protein or peptide of the invention. Modifications of peptides or portions thereof can also include reduction/ alkylation (Tarr in: *Methods of Protein Microcharacterization*, J.E. Silver ed. Humana Press, Clifton, NJ, pp 155-194 (1986)); acylation (Tarr, *supra*); chemical coupling to an appropriate carrier (Mishell and Shiigi, eds, *Selected Methods in Cellular Immunology*, WH Freeman, San Francisco, CA (1980); U.S. Patent 4,939,239; or mild formalin treatment (Marsh *International Archives of Allergy and Applied Immunology*, 41:199-215 (1971)).

To facilitate purification and potentially increase solubility of peptides of the invention, it is possible to add reporter group(s) to the peptide backbone. For example, poly-histidine can be added to a peptide to purify the peptide by immobilized metal ion affinity chromatography (Hochuli, E. et al., *Bio/Technology*, 6:1321-1325 (1988)). In addition, specific endoprotease cleavage sites can be introduced, if desired, between a reporter group and amino acid sequences of a peptide to facilitate isolation of peptides free of irrelevant sequences. In order to successfully desensitize an individual to a protein antigen, it may be necessary to increase the solubility of a peptide by adding functional groups to the peptide or by not including hydrophobic T cell epitopes or regions containing hydrophobic epitopes in the peptides or hydrophobic regions of the protein or peptide. Functional groups such as charged amino acid pairs (e.g., KK or RR) are particularly useful for increasing the solubility of a peptide when added to the amino or carboxy terminus of the peptide. Examples of modifications to peptides to increase solubility include modifications to peptide LPI-16.1 (SEQ ID NO: 23) (Fig. 2), such modified peptides include: LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO 33) , LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36) , LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), all as shown in Fig. 4.



To potentially aid proper antigen processing of T cell epitopes within a peptide, canonical protease sensitive sites can be recombinantly or synthetically engineered between regions, each comprising at least one T cell epitope. For example, charged amino acid pairs, such as KK or RR, can be introduced between regions within a peptide during recombinant construction of the peptide or added to the amino or carboxy terminus of a synthetically produced peptide. The resulting peptide can be rendered sensitive to cathepsin and/or other trypsin-like enzymes cleavage to generate portions of the peptide containing one or more T cell epitopes. In addition, as mentioned above, such charged amino acid residues can result in an increase in solubility of a peptide.

Site-directed mutagenesis of DNA encoding a peptide of the invention can be used to modify the structure of the peptide by methods known in the art. Such methods may, among others, include PCR with degenerate oligonucleotides (Ho et al., *Gene*, 77:51-59 (1989)) or total synthesis of mutated genes (Hostomsky, Z. et al., *Biochem. Biophys. Res. Comm.*, 161:1056-1063 (1989)). To enhance bacterial expression, the aforementioned methods can be used in conjunction with other procedures to change the eucaryotic codons in DNA constructs encoding protein or peptides of the invention to ones preferentially processed in *E. coli*, yeast, mammalian cells, or other prokaryotic or eukaryotic host cells.

Peptides of the present invention can also be used for detecting and diagnosing ryegrass pollinosis. For example, this could be done *in vitro* by combining blood or blood products obtained from an individual to be assessed for sensitivity to ryegrass pollen or another cross-reactive pollen such as *Dac g I*, *Poa p I* and *Phl p I*, with an isolated peptide(s) of *Lol p I*, under conditions appropriate for binding of components in the blood (e.g., antibodies, T-cells, B cells) with the peptide(s) and determining the extent to which such binding occurs. Other diagnostic methods for allergic diseases in which the protein, peptides or antibodies of the present invention will be useful include radio-allergosorbent test (RAST), paper radioimmunosorbent test (PRIST), enzyme linked immunosorbent assay (ELISA), radioimmunoassays (RIA), immuno-radiometric assays (IRMA), luminescence immunoassays (LIA), histamine release assays and IgE immunoblots.

The presence in individuals of IgE specific for at least one protein allergen and the ability of T cells of the individuals to respond to T cell epitope(s) of the protein allergen can be determined by administering to the individuals an Immediate Type Hypersensitivity test and a Delayed Type Hypersensitivity test. The individuals

are administered an Immediate Type Hypersensitivity test (see e.g., *Immunology* (1985) Roitt, I.M., Brostoff, J., Male, D.K. (eds), C.V. Mosby Co., Gower Medical Publishing, London, NY, pp. 19.2-19.18; pp. 22.1-22.10) utilizing the protein allergen or a portion thereof, or a modified form of the protein allergen or a portion thereof, each of which binds IgE specific for the allergen. The same individuals are administered a Delayed Type Hypersensitivity test prior to, simultaneously with, or subsequent to administration of the Immediate Type Hypersensitivity test. Of course, if the Immediate Type Hypersensitivity test is administered prior to the Delayed Type Hypersensitivity test, the Delayed Type Hypersensitivity test would be given to those individuals exhibiting a specific Immediate Type Hypersensitivity reaction. The Delayed Type Hypersensitivity test utilizes a modified form of the protein allergen or a portion thereof, the protein allergen produced recombinantly, or a peptide derived from the protein allergen, each of which has human T cell stimulating activity and each of which does not bind IgE specific for the allergen in a substantial percentage of the population of individuals sensitive to the allergen (e.g., at least about 75%). Those individuals found to have both a specific Immediate Type Hypersensitivity reaction and a specific Delayed Type Hypersensitivity reaction may be treated with a therapeutic composition comprising the same modified form of the protein or portion thereof, the recombinantly-produced protein allergen, or the peptide, each as used in the Delayed Type Hypersensitivity test.

Isolated peptides of the invention, when administered in a therapeutic regimen to a *Lol p I*-sensitive individual (or an individual allergic to an allergen cross-reactive with ryegrass pollen allergen such as *Dac g I*, *Poa p I* and *Phl p I*) are capable of modifying the allergic response of the individual to *Lol p I* ryegrass pollen allergen (or such cross-reactive allergen). Preferably peptides of this invention are capable of modifying the B-cell response, T-cell response or both the B-cell and the T-cell response of the individual to the allergen. As used herein, modification of the allergic response of an individual sensitive to a ryegrass pollen allergen or cross-reactive allergen can be defined as non-responsiveness or diminution in symptoms to the allergen, as determined by standard clinical procedures (See, e.g., Varney et al, *British Medical Journal*, 302:265-269 (1990)) including diminution in ryegrass pollen-induced asthmatic symptoms. As referred to herein, a diminution in symptoms includes any reduction in allergic response of an individual to the allergen after the individual has completed a treatment regimen with a peptide or protein of the invention. This diminution may be subjective (i.e., the patient feels more comfortable

in the presence of the allergen), or diminution in symptoms may be determined clinically, using standard skin tests known in the art and discussed above.

*Lol p I* peptides of the present invention having T cell stimulating activity, and thus comprising at least one T cell epitope, are particularly preferred. In referring to an epitope, the epitope will be the basic element or smallest unit of recognition by a receptor, particularly immunoglobulins, histocompatibility antigens and T cell receptors where the epitope comprises amino acids essential to receptor recognition. Amino acid sequences which mimic those of the epitopes and which are capable of down-regulating or reducing allergic response to *Lol p I* can also be used. T cell epitopes are believed to be involved in initiation and perpetuation of the immune response to a protein allergen that is responsible for the clinical symptoms of allergy. Such T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate HLA molecule on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulation. These events lead to T cell proliferation, lymphokine secretion, local inflammatory reactions, recruitment of additional immune cells to the site, and activation of the B cell cascade leading to production of antibodies. One isotype of these antibodies, IgE, is fundamentally important to the development of allergic symptoms, and its production is influenced early in the cascade of events, at the level of the T helper cell, by the nature of the lymphokines secreted.

Exposure of ryegrass pollen-sensitive patients or patients sensitive to an immunologically cross-reactive protein allergen such as *Dac g I*, *Poa p I* and *Phl p I*, to isolated *Lol p I* peptides of the present invention which comprise at least one T cell epitope and are derived from *Lol p I* protein allergen, may tolerize or anergize appropriate T cell subpopulations such that they become unresponsive to the protein allergen and do not participate in stimulating an immune response upon such exposure. In addition, administration of a peptide of the invention or portion thereof which comprises at least one T cell epitope may modify the lymphokine secretion profile as compared with exposure to the naturally-occurring *Lol p I* protein allergen or portion thereof (e.g., may result in a decrease of IL-4 and/or an increase in IL-2). Furthermore, exposure to such peptide of the invention may influence T cell subpopulations which normally participate in the response to the naturally occurring allergen such that these T cells are drawn away from the site(s) of normal exposure to the allergen (e.g., nasal mucosa, skin, and lung) towards the site(s) of therapeutic administration of the fragment or protein allergen. This redistribution of T cell

subpopulations can have the effect of ameliorating or reducing the ability of an individual's immune system to stimulate the usual immune response at the site of normal exposure to the allergen, resulting in a diminution in allergic symptoms.

The isolated *Lol p I* peptides of the invention can be used in methods of  
5 diagnosing, treating or preventing allergic reactions to *Lol p I* allergen or an immunologically related protein allergen such as *Dac g I*, *Poa p I* and *Phl p I*. Thus, the present invention provides compositions useful in allergy diagnosis and/or useful in allergy therapy comprising isolated *Lol p I* peptides or portions thereof. Such compositions will typically also comprise a pharmaceutically acceptable carrier or  
10 diluent when intended for *in vivo* administration. Therapeutic compositions of the invention may include synthetically prepared *Lol p I* peptides.

Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known techniques. *Lol p I* peptides or portions thereof may be administered to an individual in combination with,  
15 for example, an appropriate diluent, a carrier and/or an adjuvant. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutically acceptable carriers include polyethylene glycol (Wie *et al.* (1981) *Int. Arch. Allergy Appl. Immunol.*, 64:84-99) and liposomes (Strejan *et al.* (1984) *J. Neuroimmunol.*, 7:27). For purposes of inducing T-cell anergy, the therapeutic composition is  
20 preferably administered in nonimmunogenic form, i.e., it does not contain adjuvant. The therapeutic compositions of the invention are administered to ryegrass pollen-sensitive individuals or individuals sensitive to an allergen which is immunologically cross-reactive with ryegrass pollen allergen (i.e., *Dactylis glomerata*, or *Sorghum halepensis*, etc.). Therapeutic compositions of the invention may also be used in the  
25 manufacture of medicaments for treating sensitivity to ryegrass pollen allergen or an immunologically related pollen allergen.

Administration of the therapeutic compositions of the present invention to an individual to be desensitized can be carried out using known procedures at dosages and for periods of time effective to reduce sensitivity (i.e., to reduce the allergic  
30 response) of the individual to the allergen. Effective amounts of the therapeutic compositions will vary according to factors such as the degree of sensitivity of the individual to ryegrass pollen, the age, sex, and weight of the individual, and the ability of the protein or fragment thereof to elicit an antigenic response in the individual.

The active compound (i.e., protein or fragment thereof) may be administered  
35 in any convenient manner such as by injection (subcutaneous, intravenous, etc.), oral

administration, inhalation, transdermal application, or rectal administration.

Depending on the route of administration, the active compound may be coated within a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.

5           For example, preferably about 1  $\mu$ g- 3 mg and more preferably from about 20-750  $\mu$ g of active compound (i.e., protein or fragment thereof) per dosage unit may be administered by injection. Dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the  
10           therapeutic situation.

          To administer a peptide by other than parenteral administration, it may be necessary to coat the protein with, or co-administer the protein with, a material to prevent its inactivation. For example, the peptide or portion thereof may be co-administered with enzyme inhibitors or in liposomes. Enzyme inhibitors include  
15           pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan *et al.*, (1984), *J. Neuroimmunol.*, 7:27).

          The active compound may also be administered parenterally or  
~~intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene~~  
20           glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

          Pharmaceutical compositions suitable for injection include sterile aqueous solutions (where the peptides are water soluble) or dispersions and sterile powders for  
25           the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the composition intended for *in vivo* use must be sterile and must be fluid to the extent necessary to provide easy syringability. It should preferably be stable under the conditions of manufacture and storage and be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or  
30           dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. Prevention of the  
35           action of microorganisms can be achieved by various antibacterial and antifungal

agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol and sorbitol or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought  
5 about, including in the composition, an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (i.e., protein or peptide) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by  
10 filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active  
15 ingredient (i.e., protein or peptide) plus any additional desired ingredient from a previously sterile-filtered solution thereof.

When a peptide of the invention is suitably protected, as described above, the peptide may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The peptide and other ingredients may also be enclosed in a hard or soft  
20 gelatin capsule, compressed into tablets, or incorporated directly into the individual's food. For oral therapeutic administration, the active compound may be formulated with conventional excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The  
25 percentage of the composition and preparations may, of course, be varied and may conveniently be between about 5 to 80% by weight of the dosage unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit contains from about 10  $\mu$ g  
30 to about 200 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such  
35 as sucrose, lactose or saccharin or a flavoring agent such as peppermint, oil of

wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservative, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

As used herein "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the therapeutic compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

Various isolated peptides of the invention derived from ryegrass pollen protein *Lol p I* are shown in Figs. 2 and 4 (SEQ ID NO: 3-50). Peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p I* are also within the scope of the invention. As used herein a region may include the amino acid sequence of a peptide of the invention as shown in Figs. 2 and 4 (SEQ ID NO: 3-50) or the amino acid sequence of a portion of such peptide.

To obtain isolated peptides of the present invention, *Lol p I* is divided into non-overlapping peptides of desired length or overlapping peptides of desired lengths as discussed in Example 4 which can be produced recombinantly, or synthetically. Peptides comprising at least one T cell epitope are capable of eliciting a T cell response, such as T cell proliferation or lymphokine secretion, and/or are capable of inducing T cell anergy (i.e., tolerization). To determine peptides comprising at least one T cell epitope, isolated peptides are tested by, for example, T cell biology techniques, to determine whether the peptides elicit a T cell response or induce T cell anergy. Those peptides found to elicit a T cell response or to induce T cell anergy are defined as having T cell stimulating activity.

As discussed in Example 4, human T cell stimulating activity can be tested by culturing T cells obtained from an individual sensitive to *Lol p I* allergen, (i.e., an

individual who has an IgE-mediated immune response to *Lol p I* allergen) with a peptide derived from the allergen, then determining whether proliferation of T cells occurs in response to the peptide. T cell proliferation may be measured in several ways, e.g., by cellular uptake of tritiated thymidine. Stimulation indices for responses by T cells to peptides can be calculated as the maximum counts-per-minute (CPM) in response to a peptide divided by the control CPM. A stimulation index (S.I.) equal to or greater than two times the background level is considered "positive". Positive results are used to calculate the mean stimulation index for each peptide for the group of patients tested. Preferred peptides of this invention comprise at least one T cell epitope and have a mean T cell stimulation index of greater than or equal to 2.0. A peptide having a mean T cell stimulation index of greater than or equal to 2.0 in a significant number of ryegrass pollen sensitive patients tested (i.e., at least 10% of patients tested) is considered useful as a therapeutic agent. Preferred peptides have a mean T cell stimulation index of at least 2.5, more preferably at least 3.0, more preferably at least 3.5, more preferably at least 4.0, more preferably at least 5, and most preferably at least about 6. For example, peptides of the invention having a mean T cell stimulation index of at least 5, as shown in Fig. 3, include LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-17 (SEQ ID NO: 24), LPI-19 (SEQ ID NO: 26), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30). For example, peptides of the invention having a mean T cell stimulation index of at least 6, as shown in Fig. 3, include LPI-2 (SEQ ID NO: 5), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30).

In addition, preferred peptides have a positivity index (P.I.) of at least about 100, more preferably at least about 200 and most preferably at least about 300. The positivity index for a peptide is determined by multiplying the mean T cell stimulation index by the percent of individuals, in a population of individuals sensitive to ryegrass pollen (e.g., preferably at least 15 individuals, more preferably at least 30 individuals or more), who have a T cell stimulation index to such peptide of at least 2.0. Thus, the positivity index represents both the strength of a T cell response to a peptide (S.I.) and the frequency of a T cell response to a peptide in a population of individuals sensitive to ryegrass pollen. For example, as shown in Fig. 3, *Lol p I* peptide LPI-15 (SEQ ID NO: 21) has a mean S.I. of 12.2 and 11% of positive responses in the group of individuals tested resulting in a positivity index of 134.2. *Lol p I* peptides having a



positivity index of at least about 100 and a mean T cell stimulation index of at least about 4 include: LPI-2 (SEQ ID NO: 5), LPI-11 (SEQ ID NO: 15), LPI-13 (SEQ ID NO: 19), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30).

In order to determine precise T cell epitopes by, for example, fine mapping techniques, a peptide having T cell stimulating activity and thus comprising at least one T cell epitope as determined by T cell biology techniques is modified by addition or deletion of amino acid residues at either the amino or carboxy terminus of the peptide and tested to determine a change in T cell reactivity to the modified peptide. If two or more peptides which share an area of overlap in the native protein sequence are found to have human T cell stimulating activity, as determined by T cell biology techniques, additional peptides can be produced comprising all or a portion of such peptides and these additional peptides can be tested by a similar procedure. Following this technique, peptides are selected and produced recombinantly or synthetically. Examples of fine map peptides are as follows: modified versions of peptide LPI-18 (SEQ ID NO: 25) (Fig. 2) include peptides: LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42) all as shown in Fig. 4; modified versions of peptide LPI-20 (SEQ ID NO: 27) (Fig. 2) include peptides: LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), and LPI-20.6 (SEQ ID NO: 47) all as shown in Fig. 4; modified versions of peptide LPI-23 (SEQ ID NO: 30) (Fig. 2) include peptides: LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49) and LPI-23.4 (SEQ ID NO: 50) all as shown in Fig. 4.

Peptides are selected for diagnostic or therapeutic uses based on various factors, including the strength of the T cell response to the peptide (e.g., stimulation index), the frequency of the T cell response to the peptide in a population of individuals sensitive to ryegrass pollen, and the potential cross-reactivity of the peptide with other allergens from other species of grasses as discussed earlier. The physical and chemical properties of these selected peptides (e.g., solubility, stability) are examined to determine whether the peptides are suitable for use in therapeutic compositions or whether the peptides require modification as described herein. The ability of the selected peptides or selected modified peptides to stimulate human T cells (e.g., induce proliferation, lymphokine secretion) is determined.

The most preferred T cell epitope-containing peptides of the invention do not bind immunoglobulin E (IgE) of an allergic individual or bind IgE to a substantially lesser extent (e.g., at least 100 fold less and more preferably, at least 1000 fold less) than the protein allergen from which the peptide is derived. The major complications of standard immunotherapy are IgE-mediated responses such as anaphylaxis. Immunoglobulin E is a mediator of anaphylactic reactions which result from the binding and cross-linking of antigen to IgE on mast cells or basophils and the consequent release of mediators (e.g., histamine, serotonin, eosinophil chemotactic factors). Anaphylaxis in a substantial percentage of a population of individuals sensitive to *Lol p I* could be avoided by the use in immunotherapy of a peptide which do not bind IgE in a substantial percentage (e.g., at least about 75%) of a population of individuals sensitive to *Lol p I* allergen, or, if the peptides do bind IgE, such binding does not result in the release of mediators from mast cells or basophils. The risk of anaphylaxis could be reduced by the use in immunotherapy of a peptide or peptides which have reduced IgE binding. Moreover, peptides having minimal IgE stimulating activity are desirable for therapeutic effectiveness. Minimal IgE stimulating activity refers to IgE production that is less than the amount of IgE production stimulated by the native *Lol p I* protein allergen. Similarly, IL-4 production can be compared, with reduces IL-4 production indicating lessened IgE stimulating activity.

Preferred T cell epitope-containing peptides of the invention, when administered to a ryegrass pollen-sensitive individual or an individual sensitive to an allergen which is immunologically related to ryegrass pollen allergen (such as *Dac g I*, *Poa p I*, and *Phl p I*) in a therapeutic treatment regimen, are capable of modifying the allergic response of the individual to the allergen. Particularly, such preferred *Lol p I* peptides of the invention comprising at least one T cell epitope of *Lol p I* or at least two regions derived from *Lol p I*, each comprising at least one T cell epitope, when administered to an individual sensitive to ryegrass pollen are capable of modifying T cell response of the individual to the allergen, and they will thus be useful as therapeutics in addressing sensitivity to grasses.

A preferred isolated *Lol p I* peptide of the invention or portion thereof comprises at least one T cell epitope of *Lol p I* and accordingly, the peptide comprises at least approximately seven amino acid residues. For purposes of therapeutic effectiveness, preferred therapeutic compositions of the invention preferably comprise at least two T cell epitopes of *Lol p I*, and accordingly, the peptide comprises at least approximately eight amino acid residues and preferably at least fifteen amino acid

residues. Additionally, therapeutic compositions comprising preferred isolated peptides of the invention most preferably comprise a sufficient percentage of the T cell epitopes of the entire protein allergen so that a therapeutic regimen of administration of the composition to an individual sensitive to ryegrass pollen results in T cells of the individual being tolerized to the protein allergen. Synthetically produced peptides of the invention comprising up to approximately forty-five amino acid residues in length, and most preferably up to approximately thirty amino acid residues in length are particularly desirable, as increases in length may result in difficulty in peptide synthesis. Peptides of the invention may also be produced recombinantly as described above, and peptides exceeding 45 amino acids will be more easily produced recombinantly.

Peptides derived from the *Lol p I* protein allergen which exhibit T cell stimulatory properties and thus are believed to be useful therapeutics and/or intermediatea in developing tolerizing peptides comprise all or a portion of the following peptides: LPI-1 (SEQ ID NO: 3), LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8), LPI-5 (SEQ ID NO: 9), LPI-6 (SEQ ID NO: 10), LPI-7 (SEQ ID NO: 11), LPI-8 (SEQ ID NO: 12), LPI-9 (SEQ ID NO: 13), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-12 (SEQ ID NO: 17), LPI-13 (SEQ ID NO: 19), LPI-14 (SEQ ID NO: 20), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-17 (SEQ ID NO: 24), LPI-18 (SEQ ID NO: 25), LPI-19 (SEQ ID NO: 26), LPI-20 (SEQ ID NO: 27), LPI-21 (SEQ ID NO: 28), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30) (Fig. 2) wherein the portion of the peptide preferably has a mean T cell stimulation index equivalent to, or greater than the mean T cell stimulation index of the corresponding peptide from which it is derived, as shown in Fig. 3. Even more preferably peptides derived from the *Lol p I* protein allergen comprise all or a portion of the following peptides: LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8), LPI-8 (SEQ ID NO: 12), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-13 (SEQ ID NO: 19), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-19 (SEQ ID NO: 26), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30), as shown in Fig. 2. Additionally, even more preferred peptides derived from the *Lol p I* protein comprise the following peptides: LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID

NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30), all as shown in Fig. 2. Additional preferred peptides believed to T cell stimulating activity comprise the following peptides: LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50).

One embodiment of the present invention features a peptide or portion thereof of *Lol p I* which comprises at least one T cell epitope of the protein allergen and has a formula  $X_n-Y-Z_m$ . According to the formula, Y is an amino acid sequence selected from the group consisting of LPI-1 (SEQ ID NO: 3), LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8), LPI-5 (SEQ ID NO: 9), LPI-6 (SEQ ID NO: 10), LPI-7 (SEQ ID NO: 11), LPI-8 (SEQ ID NO: 12), LPI-9 (SEQ ID NO: 13), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-12 (SEQ ID NO: 17), LPI-13 (SEQ ID NO: 19), LPI-14 (SEQ ID NO: 20), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-17 (SEQ ID NO: 24), LPI-18 (SEQ ID NO: 25), LPI-19 (SEQ ID NO: 26), LPI-20 (SEQ ID NO: 27), LPI-21 (SEQ ID NO: 28), LPI-22 (SEQ ID NO: 29), LPI-23 (SEQ ID NO: 30), LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50) and preferably selected from the group consisting of LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8), LPI-8 (SEQ ID NO: 12), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-13 (SEQ ID NO: 19), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-19 (SEQ ID NO: 26), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), LPI-23 (SEQ ID NO: 30), LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID

## 2157596

NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50) and more preferably selected from the group consisting of LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), LPI-23 (SEQ ID NO: 30), LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50), and most preferably selected from the group consisting of LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50). In addition,  $X_n$  are amino acid residues contiguous to the amino terminus of Y in the amino acid sequence of the protein allergen and  $Z_m$  are amino acid residues contiguous to the carboxy terminus of Y in the amino acid sequence of the protein allergen. In the formula, n is 0-30 and m is 0-30. Preferably, the peptide or portion thereof has a mean T cell stimulation index equivalent to greater than the mean T cell stimulation index of Y as shown in Fig. 3. Preferably, amino acids comprising the amino terminus of X and the carboxy terminus of Z are selected from charged amino acids, i.e., arginine (R), lysine (K), histidine (H), glutamic acid (E) or aspartic acid (D); amino acids with reactive side chains, e.g., cysteine (C), asparagine (N) or glutamine (Q); or amino acids with sterically small side chains, e.g.,

2157596

alanine (A) or glycine (G). Preferably n and m are 0-5; most preferably n + m is less than 10.

Another embodiment of the present invention provides peptides comprising at least two regions, each region comprising at least one T cell epitope of *Lol p I* and accordingly each region comprises at least approximately seven amino acid residues. These peptides comprising at least two regions can comprise up to 100 or more amino acid residues but preferably comprise at least about 14, even more preferably at least about 20, and most preferably at least about 30 amino acid residues of the *Lol p I* allergen. If desired, the amino acid sequences of the regions can be produced and joined by a linker to increase sensitivity to processing by antigen-presenting cells. Such linker can be any non-epitope amino acid sequence or other appropriate linking or joining agent. To obtain preferred peptides comprising at least two regions, each comprising at least one T cell epitope, the regions are arranged in the same or a different configuration from a naturally-occurring configuration of the regions in the allergen. For example, the regions containing T cell epitope(s) can be arranged in a noncontiguous configuration and can preferably be derived from the same protein allergen. Noncontiguous is defined as an arrangement of regions containing T cell epitope(s) which is different than that of the native amino acid sequence of the protein allergen from which the regions are derived. Furthermore, the noncontiguous regions containing T cell epitopes can be arranged in a nonsequential order (e.g., in an order different from the order of the amino acids of the native protein allergen from which the region containing T cell epitope(s) are derived in which amino acids are arranged from an amino terminus to a carboxy terminus). A peptide of the invention can comprise at least 15%, at least 30%, at least 50% or up to 100% of the T cell epitopes of *Lol p I*.

The individual peptide regions can be produced and tested to determine which regions bind immunoglobulin E specific for *Lol p I* and which of such regions would cause the release of mediators (e.g., histamine) from mast cells or basophils. Those peptide regions found to bind immunoglobulin E and to cause the release of mediators from mast cells or basophils in greater than approximately 10-15% of the allergic sera tested are preferably not included in the peptide regions arranged to form preferred peptides of the invention.

Examples of preferred peptide regions which do not bind to IgE (data not shown) include: LPI-1 (SEQ ID NO: 3), LPI-1.1 (SEQ ID NO: 4), LPI-2 (SEQ ID NO: 5), LPI-3 (SEQ ID NO: 6), LPI-4 (SEQ ID NO: 7), LPI-4.1 (SEQ ID NO: 8),

LPI-5 (SEQ ID NO: 9), LPI-6 (SEQ ID NO: 10), LPI-7 (SEQ ID NO: 11), LPI-8 (SEQ ID NO: 12), LPI-9 (SEQ ID NO: 13), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-12 (SEQ ID NO: 17), LPI-13 (SEQ ID NO: 19), LPI-14 (SEQ ID NO: 20), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-16.1 (SEQ ID NO: 23), LPI-17 (SEQ ID NO: 24), LPI-18 (SEQ ID NO: 25), LPI-19 (SEQ ID NO: 26), LPI-20 (SEQ ID NO: 27), LPI-21 (SEQ ID NO: 28), LPI-22 (SEQ ID NO: 29), LPI-23 (SEQ ID NO: 30), LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), LPI-16.10 (SEQ ID NO: 38), LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42), LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), LPI-20.6 (SEQ ID NO: 47), LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49), and LPI-23.4 (SEQ ID NO: 50), the amino acid sequences of such regions being shown in Figs. 2 or 4, or portions of said regions comprising at least one T cell epitope.

Preferred peptides comprise various combinations of two or more of the above-discussed preferred regions, or a portion thereof. Preferred peptides comprising a combination of two or more regions (each region having an amino acid sequence as shown in Fig. 2 or Fig. 4), include the following:

- 20 LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);
- 25 LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), and LPI-11 (SEQ ID NO: 15);
- LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16 (SEQ ID NO: 22);
- 30 LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16.1 (SEQ ID NO: 23);
- LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16.1 (SEQ ID NO: 23);

- LPI-10 (SEQ ID NO:14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), and LPI-20 (SEQ ID NO: 27);
- 5 LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30);
- LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), and LPI-20 (SEQ ID NO: 27);
- 10 LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);
- LPI-18 (SEQ ID NO: 25) and LPI-20 (SEQ ID NO: 27);
- 15 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27) and LPI-23 (SEQ ID NO: 30);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27) and LPI-16.1 (SEQ ID NO: 23);
- 
- 20 ~~LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30) and LPI-16.1 (SEQ ID NO: 23);~~
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23) and LPI-11 (SEQ ID NO: 15);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23) and LPI-4.1 (SEQ ID NO: 8);
- 25 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-4.1 (SEQ ID NO: 8) and LPI-22 (SEQ ID NO: 29);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-11 (SEQ ID NO: 15) and LPI-4.1 (SEQ ID NO: 8);
- 30 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-11 (SEQ ID NO: 15), LPI-4.1 (SEQ ID NO: 8) and LPI-22 (SEQ ID NO: 29);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);
- 35



LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-16.1 (SEQ ID NO: 23), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30); and LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-16.1 (SEQ ID NO: 23) and LPI-22 (SEQ ID NO: 29).

5

Additional preferred peptides comprising various combinations of two or more of the above discussed preferred regions include:

- 10 LPI-16.2 (SEQ ID NO: 31), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);
- LPI-16.3 (SEQ ID NO: 32), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);
- LPI-16.4 (SEQ ID NO: 33), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);
- 15 LPI-16.5 (SEQ ID NO: 34), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);
- LPI-16.6 (SEQ ID NO: 35), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);
- LPI-16.7 (SEQ ID NO: 36), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);
- 
- 20 LPI-16.9 (SEQ ID NO: 37), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30); and
- LPI-16.10 (SEQ ID NO: 38), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30).

25 In yet another aspect of the present invention, a composition is provided comprising at least two peptides (e.g., a physical mixture of at least two peptides), each comprising at least one T cell epitope of *Lol p I*. Such compositions can be in the form of a composition additionally with a pharmaceutically acceptable carrier of diluent for therapeutic uses, or with conventional non-pharmaceutical excipients for reagent use. When used therapeutically, an effective amount of one or more of such

30 compositions can be administered simultaneously or sequentially to an individual sensitive to ryegrass pollen.

In another aspect of the invention, combinations of *Lol p I* peptides are provided which can be administered simultaneously or sequentially. Such

35 combinations may comprise therapeutic compositions comprising only one peptide, or

more peptides if desired. Such compositions may be used simultaneously or sequentially in preferred combinations.

Preferred compositions and preferred combinations of *Lol p I* peptides which can be administered or otherwise used simultaneously or sequentially (comprising  
 5 peptides having amino acid sequences shown in Fig. 2) include the following combinations:

- 10 LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16 (SEQ ID NO: 22), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);
- LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), and LPI-11 (SEQ ID NO: 15);
- 15 LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16 (SEQ ID NO: 22);
- LPI-3 (SEQ ID NO: 6), LPI-4.1 (SEQ ID NO: 8), LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16.1 (SEQ ID NO: 23);
- 
- 20 LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), and LPI-16.1 (SEQ ID NO: 23);
- LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), and LPI-20 (SEQ ID NO: 27);
- 25 LPI-10 (SEQ ID NO: 14), LPI-11 (SEQ ID NO: 15), LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30);
- LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), and LPI-20 (SEQ ID NO: 27);
- 30 LPI-15 (SEQ ID NO: 21), LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);
- LPI-18 (SEQ ID NO: 25) and LPI-20 (SEQ ID NO: 27);

- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27) and LPI-23 (SEQ ID NO: 30);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27) and LPI-16.1 (SEQ ID NO: 23);
- 5 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30) and LPI-16.1 (SEQ ID NO: 23);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23) and LPI-11 (SEQ ID NO: 15);
- 10 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23) and LPI-4.1 (SEQ ID NO: 8);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-4.1 (SEQ ID NO: 8) and LPI-22 (SEQ ID NO: 29);
- 15 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-11 (SEQ ID NO: 15) and LPI-4.1 (SEQ ID NO: 8);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-23 (SEQ ID NO: 30), LPI-16.1 (SEQ ID NO: 23), LPI-11 (SEQ ID NO: 15), LPI-4.1 (SEQ ID NO: 8) and LPI-22 (SEQ ID NO: 29);
- 20 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-22 (SEQ ID NO: 29), and LPI-23 (SEQ ID NO: 30);
- LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-16.1 (SEQ ID NO: 23), LPI-22 (SEQ ID NO: 29) and LPI-23 (SEQ ID NO: 30); and
- 25 LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), LPI-16.1 (SEQ ID NO: 23) and LPI-22 (SEQ ID NO: 29).

Additional preferred compositions and preferred combinations of *Lol p I* peptides which can be administered or used simultaneously or sequentially (comprising peptides having amino acid sequences shown in Figs. 2 or 4) include the following combinations:

30

- LPI-16.2 (SEQ ID NO: 31), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);
- LPI-16.3 (SEQ ID NO: 32), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);

LPI-16.4 (SEQ ID NO: 33), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 LPI-16.5 (SEQ ID NO: 34), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 5 LPI-16.6 (SEQ ID NO: 35), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 LPI-16.7 (SEQ ID NO: 36), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30);  
 LPI-16.9 (SEQ ID NO: 37), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30); and  
 10 LPI-16.10 (SEQ ID NO: 38), LPI-18 (SEQ ID NO: 25), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30).

In each of the above preferred compositions, peptides LPI-16.1 (SEQ ID NO: 23), LPI-18 (SEQ ID NO: 23), LPI-20 (SEQ ID NO: 27), and LPI-23 (SEQ ID NO: 30) may be substituted as follows: peptide LPI-16.1 (SEQ ID NO: 23) (Fig. 2) may be substituted with LPI-16.2 (SEQ ID NO: 31), LPI-16.3 (SEQ ID NO: 32), LPI-16.4 (SEQ ID NO: 33), LPI-16.5 (SEQ ID NO: 34), LPI-16.6 (SEQ ID NO: 35), LPI-16.7 (SEQ ID NO: 36), LPI-16.9 (SEQ ID NO: 37), and LPI-16.10 (SEQ ID NO: 38), all as shown in Fig. 4; peptide LPI-18 (SEQ ID NO: 25) (Fig. 2) may be substituted with peptides LPI-18.5 (SEQ ID NO: 39), LPI-18.6 (SEQ ID NO: 40), LPI-18.7 (SEQ ID NO: 41), LPI-18.8 (SEQ ID NO: 42) all as shown in Fig. 4; peptide LPI-20 (SEQ ID NO: 27) may be substituted with peptides LPI-20.2 (SEQ ID NO: 43), LPI-20.3 (SEQ ID NO: 44), LPI-20.4 (SEQ ID NO: 45), LPI-20.5 (SEQ ID NO: 46), and LPI-20.6 (SEQ ID NO: 47) all as shown in Fig. 4; peptide LPI-23 (SEQ ID NO: 30) may be substituted with peptides LPI-23.1 (SEQ ID NO: 48), LPI-23.2 (SEQ ID NO: 49) and LPI-23.4 (SEQ ID NO: 50), all as shown in Fig. 4.

The present invention is further illustrated by the following non-limiting Figures and Examples.

30

### EXAMPLES

#### Example 1 - Isolation and Cloning of Nucleic Acid Sequence Coding for *Lol p I*

Total mRNA was extracted from mature ryegrass pollen by the phenol method of Herrin and Michaels, *supra*. Double-stranded cDNA was synthesized from 1µg of

35

total mRNA using a commercially available kit (cDNA SYNTHESIS SYSTEM PLUS KIT, BRL, Gaithersburg, MD). After a phenol extraction and ethanol precipitation, the cDNA was blunted with T4 DNA polymerase (Promega, Madison, WI) and ligated to ethanol-precipitated, self-annealed AT and AL oligonucleotides for use in a  
 5 modified Anchored PCR reaction, according to the method in Rafnar *et al.* (1991), *J. Biol. Chem.*, 266: 1229-1236; Frohman *et al.* (1990), *Proc. Natl. Acad. Sci. USA*, 85:8998-9002; and Roux *et al.* (1990), *BioTech.*, 8: 48-57. Oligonucleotide AT has the sequence 5'-GGGTCTAGAGGTACCGTCCGATCGATCATT-3' (SEQ ID NO: 71) (Rafnar *et al. supra*). Oligonucleotide AL has the sequence  
 10 AATGATCGATGCT (SEQ ID NO: 72) (Rafnar *et al. supra*).

Polymerase chain reactions (PCR) were carried out using a commercially available kit (GeneAmp® DNA Amplification kit, Perkin Elmer Cetus, Norwalk, CT) whereby 10 µl 10x buffer containing dNTPs were mixed with 1 µg each of primer AP, which has the sequence 5'-GGGTCTAGAGGTACCGTCCG-3' (SEQ ID NO: 73)  
 15 (Rafnar *et al. supra*) and LpA-5, which has the sequence 5'-CCCTGCAGATTATTTGAGATCTTGAG-3' (SEQ ID NO: 74), cDNA (3-5 µl of a 20 µl linker cDNA reaction mix), 0.5 µl Amplitaq DNA polymerase, and distilled water to 100 µl.

---

Nucleotides 1 through 8 (5'-CCCTGCAG) of LpA-5 correspond to a Pst I site  
 20 added for cloning purposes; the remaining nucleotides correspond to the non-coding strand sequence complementary to nucleotides 483 through 500 as shown in Fig. 6.

The samples were amplified with a programmable thermal controller (MJ Research, Inc., Cambridge, MA). The first 5 rounds of amplification consisted of denaturation at 94°C for 1 minute, annealing of primer to the template at 45°C for 1.5  
 25 minutes, and chain elongation at 70°C for 2 minutes. The final 20 rounds of amplification consisted of denaturation as above, annealing at 55°C for 1.5 minutes, and elongation as above. Five percent (5 µl) of this initial amplification was then used in a secondary amplification whereby 10 µl 10x buffer containing dNTPs was mixed with 1 µg each of primer AP and primer LpA-3, which has the sequence 5'-  
 30 CCCTGCAGTCATGCTCACTTGGCCGAGTA-3' (SEQ ID NO: 75), 0.5 µl Amplitaq DNA polymerase, and distilled water to 100 µl. The secondary PCR reaction was performed as described herein. Nucleotides 1 through 8 (5'-CCCTGCAG-3') of LpA-3 correspond to a Pst I site added for cloning purposes; nucleotides 9 through 12 (5'-TCA-3') correspond to the complementary sequence for a new stop codon, and the  
 35 remaining nucleotides correspond to the non-coding strand sequence complementary

2157596

to nucleotides 793 through 810 of the full length clone of *Lol p I* as shown in Fig. 1, including translated sequence of *Lol p I* (Fig. 1), the native stop codon and 3' untranslated sequence.

Amplified DNA was recovered by sequential chloroform, phenol, and  
 5 chloroform extractions, followed by precipitation at -20°C with 0.5 volumes of 7.5 ammonium acetate and 1.5 volumes of isopropanol. After precipitation and washing with 70% ethanol, the DNA was simultaneously digested with *Xba I* and *Pst I* in a 15 µl reaction and electrophoresed through a preparative 3% GTG NuSieve low melt gel (FMC, Rockport, ME). The appropriate sized DNA band was visualized by EtBr  
 10 staining, excised, and ligated into appropriately digested M13mp18 for sequencing by the dideoxy chain termination method (Sanger *et al.* (1977), *Proc. Natl Acad Sci USA*, 74: 5463-5476) using a commercially available sequencing kit (Sequenase kit, U.S. Biochemicals, Cleveland, OH).

Both strands were sequenced using M13 forward and reverse primers (N.E.  
 15 BioLabs, Beverly, MA) and internal sequencing primers LpA-13, LpA-12, LpA-9, LpA-2, LpA-7, LpA-10, and LpA-1A. LpA-13 has the sequence 5'-GAGTACGGCGACAAGTGGC-3' (SEQ ID NO: 76), which corresponds to nucleotides 121 through 139 as shown in Fig. 1. LpA-12 has the sequence 5'-TTCGAGATCAAGTGCACC-3' (SEQ ID NO: 77), which corresponds to nucleotides  
 20 310 through 318 as shown in Fig. 1. LpA-9 has the sequence 5'-GTGACAGCCTCGCCGG-3' (SEQ ID NO: 78), which corresponds to the non-coding strand sequence complementary to nucleotides 335 through 350 as shown in Fig. 1. LpA-2 has the sequence 5'-GGGAATTCCATGGCGAAGAAGGGC-3' (SEQ ID NO: 79). Nucleotides 1 through 7 (5'-GGGATT-3') of LpA 2 correspond to part  
 25 of an Eco-RI restriction site added for cloning purposes; the remaining sequence of LpA-2 corresponds to nucleotides 425 through 441 of Fig. 1. LpA-7 has the sequence 5'-GTGCCGTCCGGGTACT-3' (SEQ ID NO: 80), and corresponds to non-coding strand sequence complementary to nucleotides 503 through 518 of Fig. 1. LpA-10 has the sequence 5'-CCGTCGACGTACTTCA-3' (SEQ ID NO: 81), which corresponds to  
 30 non-coding strand sequence complementary to nucleotides 575 through 590 of Fig. 1. LpA-1A has the sequence 5'-GGAGTCGTGGGGAGCAGTC-3' (SEQ ID NO: 82), which corresponds to nucleotides 654 through 672 of Fig. 1.

Multiple clones from several independent PCR reactions were sequenced. The  
 nucleotide (SEQ ID NO: 1) and deduced amino acid sequences (SEQ ID NO: 2) of a  
 35 representative clone of *Lol p I*, clone 26.j are shown in Fig. 1. As shown in Fig.1, the

nucleic acid sequence coding for *Lol p I* has an open reading frame beginning with an ATG initiation codon at nucleotides 16-18 ending with a TGA stop codon at nucleotides 805-807. The translated protein has a deduced amino acid sequence of 263 amino acids with a predicted molecular weight of 28.4 kD and a pI of 5.55. The  
5 initiating methionine is numbered amino acid -23, with amino acid numbered +1 corresponding to the NH<sub>2</sub>-terminus of the mature protein, as defined by amino acid sequencing (Cottam *et al.* (1986), *Biochem. J.*, 234: 305-310). Amino acids -23 through -1 (Fig.1), correspond to a leader sequence that is cleaved to yield the mature protein; the mature protein is therefore composed of 240 amino acids and has a  
10 predicted molecular weight of 26.1 kD and a pI of 5.38. There is a single potential N-linked glycosylation site at amino acid 9.

Amino acids 1 through 30 of clone 26.j (Fig. 1) correspond exactly to the published sequence of the NH<sub>2</sub> terminus of *Lol p I* (Cottam *et al.*, *supra*). Amino acids 213 through 240 of clone 26.j (Fig. 1) correspond exactly to the published internal  
15 amino acid sequence of *Lol p I* (Esch and Klapper (1989), *Mol. Immunol.*, 26: 557-561).

#### Example 2 - Identification of Polymorphisms in *Lol p I*

---

A number of polymorphisms in the nucleotide sequence coding for *Lol p I* were  
20 discovered during the amplification and sequencing of different *Lol p I* clones. Some of the polymorphisms cause an amino acid change relative to that of clone 26.j, while others are silent polymorphisms that do not cause an amino acid change. The polymorphisms found in the sequence coding for *Lol p I* are summarized in Table 1. The nucleotide base numbers are those of the sequence of clone 26.j shown in Fig 1.

2157596

**Table 1**  
**Polymorphisms Detected in *Lol p I***

5	Nucleotide Polymorphism	Amino Acid Polymorphism
1	GGC <sub>215</sub> →GGA/GGT	None
2	G <sub>234</sub> AC <sub>236</sub> →GAT	D <sub>45</sub> →N
3	GTT <sub>239</sub> →GTC	None
4	CGT <sub>351</sub> →CGC	None
5	GGC <sub>356</sub> →GGT	None
6	AAC <sub>389</sub> →AAT	None
7	CCC <sub>396</sub> →CCT	None
8	CAT <sub>413</sub> →CAC	None
9	GCC <sub>434</sub> →GCA	None
10	GAC <sub>530</sub> →GAT	None
11	GG <sub>532</sub> C→GAC	G <sub>144</sub> →D
12	CCG <sub>542</sub> →CCA	None
13	ACA <sub>545</sub> →ACG	None
14	GC <sub>562</sub> T→GGT	A <sub>154</sub> →G
15	CTC <sub>581</sub> →CTG	None
16	GCG <sub>626</sub> →GCC	None
17	ATC <sub>782</sub> →ATT	None
18	CCT <sub>785</sub> →CCC	None

All confirmed nucleotide polymorphisms (polymorphisms observed in the sequence analysis of clones from two independent PCR reactions) are shown relative to the sequence of clone 26.j (Fig.1) (SEQ ID NO: 1). The polymorphic residues in their respective codon triplets are numbered. Productive amino acid changes are also shown; most nucleotide polymorphisms are silent and do not result in an amino acid change. Twenty-eight potential polymorphisms have only been observed in clones from single PCR reactions. Seventeen of these 28 potential polymorphisms are silent mutations and do not result in an amino acid polymorphism; the remaining 11 potential polymorphic sites would result in the following amino acid changes, specifically: T<sub>11</sub>



→M, A49→V, R67→S, K79→R, V90→I, Q133→R, I162→T, V173→E, I187→T, V223→F and K232→R. The potential polymorphism at amino acid 223 (V223→F) has been previously reported. (Perez *et al.*, *supra*)

5    **Example 3 - Human IgE reactivity to Purified Recombinant and Native *Lol p I***

Cloned DNA encoding *Lol p I* and *Lol p IX* was expressed in *E. coli* and purified on a Ni-chelating affinity column. Monoclonal antibodies were also used to affinity purify and distinguish isoforms of these and native grass proteins. The recombinant *Lol p I* was compared to biochemically purified native *Lol p I* and *Lol p*  
10    *IX* in mAb and human IgE reactivity studies (data not shown). The reactivity of human IgE to the recombinant and native forms was equivalent when measured by direct binding ELISA. In competition assays, the native *Lol p I* and *Lol p IX* proteins could completely inhibit IgE binding to *Lol p* soluble pollen extract (SPE), whereas the recombinant form of *Lol p I* and *Lol p IX* could only partially inhibit IgE binding to the  
15    extract. However, the recombinant *Lol p I* and *Lol p IX* was still active in these competition assays. These assays were then extended to western blot inhibition studies; both methods confirm the previous finding that Group I and Group IX constitute one of the major allergenic proteins of *Lolium perenne* grass pollen. Furthermore, the *Lol p I* and *Lol p IX* native and recombinant allergens showed inhibition of grass allergic  
20    patient IgE binding to soluble pollen extracts of other grass species (*Dac g*, *Phl p* and *Poa p*). The degree to which *Lol p I* and *Lol p IX* proteins successfully compete for IgE binding to these other grasses implies a hierarchy of homology between the species. These studies confirm and extend the findings of shared IgE epitopes between temperate grass allergens.

25    The procedures used for the foregoing examples were as follows:

#### Extraction and Depigmentation of Allergens

Defatted *Lol p I* pollen was extracted twice, overnight at 4°C in 50mM phosphate buffer, 15mM NaCl, pH 7.2 and protease inhibitors (PMSF, Luepeptin, SPTI and pepstatin). The extract was then depigmented by batch absorption with DE-52 (Whatman) in 50mM phosphate buffer, 0.3M NaCl, pH 7.2.

#### Biochemical Purification of *Lol p I* Allergen

Depigmented *Lol p I* extract was dialyzed into H<sub>2</sub>O, pH 8.0 by addition of NH<sub>4</sub>OH. This material was loaded onto a DE-52 column and eluted stepwise with 1mM, 4.5mM and 7.5mM NaH<sub>2</sub>PO<sub>4</sub>. The majority of the Group I allergens was eluted with 4.5mM NaH<sub>2</sub>PO<sub>4</sub>. A further separation of Group I was accomplished by running this DE-52 enriched fraction over A (26/60) superdex 75 column (Pharmacia).

#### Immunoaffinity Purification of *Lol p IX* Allergen

1B9 ascites was precipitated by 50% (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, followed by purification over Q-sepharose (Pharmacia). Purified 1B9, an anti-*Lol p IX* antibody, was then coupled to Affigel-10 (Biorad), according to the manufacturer's instructions. Either depigmented pollen extract or DE-52 enriched material was circulated over the 1B9 affigen column overnight at 4°C. The column was washed with PBS, PBS + 0.5M NaCl and then eluted with 0.1M Glycine, pH 2.7. Eluted *Lol p IX* fractions were neutralized with 1M tris-base, pH 11.

#### Expression and Purification of Recombinant *Lol p I*

*Lol p I* cDNA's encoding from the first amino acid of the mature protein to the stop codon were ligated into pET11dΔHR containing a leader which encoded 6 histidines. The HIS<sub>6</sub> was used for purification over a nickel-NTA agarose column (Qiagen). r*Lol p I* was expressed in *E. coli*.

#### SDS-PAGE, Electrophoresis and Immunoblotting

Electrophoresis was performed using 12.5% polyacrylamide gels. The samples were run under reducing conditions (4 hours at 40mA constant current). After electrophoresis the protein was transferred to nitrocellulose membrane (1.5 hours at 1.5A). The blots were stained with 1% India ink, and then blocked with 1% defatted milk, 1% FCS in Tween solution (2mM Tris-HCl pH 7.5, 0.71M NaCl, and 0.05% Tween 20) for 1 hour. The human plasma samples were pre-absorbed with blank

nitrocellulose for 1.5 hours prior to incubation. Blot sections were incubated with 1st antibodies diluted in 1% milk/Tween solution overnight at room temperature (RT). The blot sections were washed three times and incubated in the appropriate biotinylated 2nd AB (1:2500) for 2 hours at RT. The blot sections were washed three times and finally incubated with  $^{125}\text{I}$ -streptavidin 1 hour at RT. The sections were washed extensively to remove unbound label and exposed to film. Autoradiography was carried out at  $-80^{\circ}\text{C}$ .

#### Direct, Competition and Depletion ELISA

10        Microtiter plates were coated with 2.5-10.0  $\mu\text{g/mL}$  of coating antigen (grall soluble pollen extract (SPE), *Lol p I*, *Lol p IX*, *Lol p IX*, recombinant *Lol p I*, and/or recombinant *Lol p IX*) in PBS at 100  $\mu\text{L/well}$  and incubated overnight at  $4^{\circ}\text{C}$ . The plates were washed three times between each step with PBS-T (Phosphate buffered saline + 0.05% Tween 20). The unbound antigen was removed and the plate blocked with 300  $\mu\text{L/well}$  of 1MG/ML PVP in 0.5% gelatin/PBS for one hour at room temperature (RT). All subsequent reagents were added at 100  $\mu\text{L/well}$  for direct ELISA, serially diluted human plasma was added to duplicate wells and incubated overnight at  $4^{\circ}\text{C}$ . This was followed by biotinylated goat anti-human IgE (1:1,000) for 1 hour at RT; then streptavidin-HRPO (1:10,000) for 1 hour at RT. TMB  
20        substrate and  $\text{H}_2\text{O}_2$  were freshly mixed and added; the color was allowed to develop for 2-5 minutes. The reaction was stopped by the addition of 1M phosphoric acid. The plates were read on a dynatech plate reader at 450NM and the absorbances of duplicate wells were averaged.

25        For the competition ELISA, the human plasma samples were mixed with an equal volume of serially diluted antigen or with PBS-T (as a control). These samples were incubated overnight at  $4^{\circ}\text{C}$  before addition to the microtiter plate and performing the remaining steps of the ELISA as stated above.

30        For the depletion ELISA, the human plasma was pre-incubated on antigen or PBS coated wells, collected and re-incubated on freshly coated wells. The ELISA was then performed as outlined above.

**EXAMPLE 4 - Human T Cell Studies with *Lol p I*****Synthesis of Overlapping Peptides**

- 5 Ryegrass *Lol p I* overlapping peptides were synthesized using standard Fmoc/tBoc synthetic chemistry and purified by Reverse Phase HPLC. Fig. 2 shows *Lol p I* peptides used in these studies (SEQ ID NO: 3-30). The peptide names are consistent throughout.

**IgE Binding Studies with overlapping peptides**

- 10 None of the peptides shown in Fig. 2 bound a detectable amount of IgE from pooled human plasma when analyzed in a solid phase ELISA assay (data not shown). The procedure for the ELISA assay with the overlapping peptides was substantially the same as that described in Example 3.

**T Cell Responses to Ryegrass Antigen Peptides**

- 15 Peripheral blood mononuclear cells (PBMC) were purified by lymphocyte separation medium (LSM) centrifugation of 60 ml of heparinized blood from grass-allergic patients who exhibited clinical symptoms of seasonal rhinitis and were MAST and/or skin test positive for grass. Long-term T cell lines were established by  
20 stimulation of  $2 \times 10^6$  PBL/ml in bulk cultures of complete medium (RPMI-1640, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin,  $5 \times 10^{-5}$  M 2-mercaptoethanol, and 10 mM HEPES, supplemented with 5% heat-inactivated human AB serum) with 25 mg/ml of purified native *Lol p I* (95% pure with a single band on protein gel) for 6 days at 37°C in a humidified 5% CO<sub>2</sub> incubator to select for *Lol p I* reactive T Cells.  
25 This amount of priming antigen was determined to be optimal for the activation of T cells from most grass-allergic patients. Viable cells were purified by LSM centrifugation and cultured in complete medium, supplemented with 5 units recombinant human IL-2/ml and 5 units recombinant human IL-4/ml for up to 3 weeks until the cells no longer responded to lymphokines and were considered "rested." The  
30 ability of the T cells to proliferate to selected peptides, recombinant *Lol p I* (r*Lol p I*), purified native *Lol p I*, recombinant *Lol p IX* (r*Lol p IX*), or *Der p I* (r*Der p I*) was then assessed. For assay,  $2 \times 10^4$  rested cells were restimulated in the presence of  $2 \times 10^4$  autologous Epstein-Barr virus (EBV)-transformed B cells (prepared as described below) with 2-50 mg/ml of r*Lol p I*, purified native *Lol p I*, r*Der p I*, or r*Lol p IX*,  
35 in a volume of 200 ml complete medium in duplicate wells in 96-well round-

2157596

bottom plates for three days. Each well then received 1 mCi tritiated thymidine for 16-20 hours. The counts incorporated were collected onto glass fiber filter mats and processed for liquid scintillation counting. The varying antigen dose in assays with *rLol p I*, purified native *Lol p I*, and recombinant *Lol p IX* and several antigenic peptides (i.e., peptides that induce an immune response, or, specifically, a positive T cell response in these assays) synthesized as described above were determined. The titrations were used to optimize the dose of peptides in T cell assays. The maximum response in a titration of each peptide is expressed as the stimulation index (S.I.). The S.I. is the counts per minute (CPM) incorporated by cells in response to peptide, divided by the CPM incorporated by cells in medium only. An S.I. value equal to or greater than 2 times the background level is considered "positive" and indicates that the peptide contains a T cell epitope. The positive results were used in calculating mean stimulation indices for each peptide for the group of patients tested. The results (not shown) demonstrate that one patient responds well to *rLol p I* and purified native *Lol p I*, as well as to *Lol p I* peptides but not to recombinant *Der p I*. This indicated that *Lol p I* T cell epitopes are recognized by T cells from this particular allergic patient and that *rLol p I* contains such T cell epitopes. T cells from the majority of patients also reacted to *rLol p IX*, suggesting a presence of *Lol p IX* antigen in the purified native *Lol p I* prep that was used to prime T cells.

The above procedure was followed with a number of other patients. Individual patient results were used in calculating the mean S.I. for each peptide if the patient responded to the *Lol p I* protein at an S.I. of 2.0 or greater and the patient responded to at least one peptide derived from *Lol p I* at an S.I. of 2.0 or greater. A summary of positive experiments from 35 patients is shown in Fig. 3. All 35 T cell lines responded to purified native *Lol p I* and *rLol p I*. The numbers enclosed in the parentheses denote percentage of patients responding to that particular peptide. The bar represents the positivity index for each peptide (% of patients responding multiplied by mean S.I.).

#### Preparation of EBV-transformed B Cells for Use as Antigen-presenting Cells

Autologous EBV-transformed cell lines were derived by incubating  $5 \times 10^6$  PBL with 1 ml of B-59/8 Marmoset cell line (ATCC CRL1612, American Type Culture Collection, Rockville, MD) conditioned medium in the presence of 1 mg/ml phorbol 12-myristate 13-acetate (PMA) at 37°C for 60 minutes in 12x75 mm polypropylene round-bottom Falcon snap cap tubes (Becton Dickinson Labware, Lincoln Park, NJ).

These cells were then diluted to  $1.25 \times 10^6$  cells/ml in the RPMI-1640 medium that was supplemented with 10% heat-inactivated fetal bovine serum in place of the 5% human AB serum and cultured in 200 ml aliquots in flat-bottom culture plates until visible colonies were detected. They were then transferred to larger wells until the cell lines were established.

Those skilled in the art will appreciate that the invention described is susceptible to variations and modification other than those specifically described. It is understood that the invention includes all such variations and modifications. The invention also includes all steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

#### Example 5 - Cloning and Expression of *Dac g I*, *Poa p I* and *Phl p I*

##### 15 A. Cloning of *Dac g 1*.

RNA was obtained from the pollen of *Dactylis glomerata* using a standard acid phenol extraction procedure (Sambrook *et al.* (1989), *Molecular Cloning: A laboratory manual. 2nd Edition.*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). This and other pollens described below were purchased from Greer Laboratories (Lenoir, NC). Single and double stranded cDNA was prepared from total *D. glomerata* RNA using the BRL cDNA Synthesis System (Gaithersburg, MD), blunted using standard procedures (Sambrook *et al.* (1989) *supra*), and ligated to self-annealed oligonucleotides AT (5'-GGGTCTAGAGGTACCGTCCGATCGATCATT-3') (SEQ ID NO: 71) and AL (5'-AATGATCGATGCT-3') (SEQ ID NO: 72) (Rafnar *et al.* (1991), *J. Biol. Chem.*, 266:1229-1236).

The amino portion of the gene encoding *Dac g 1*, including 5' untranslated sequence, nucleotide sequence encoding the predicted leader sequence and nucleotide sequence encoding the first portion of the mature protein, was cloned using the polymerase chain reaction (PCR). Oligonucleotide primers AP-2 (5'-GGGTCTAGAGGTACCGTCC-3') (SEQ ID NO: 83) and LpA-7 (5'-GTGCCGTCCGGGTACT-3') (SEQ ID NO: 80) were used in a primary amplification. Oligonucleotide primers AP-2 and LpA-9 (5'-GTGACAGCCTCGCCGG-3') (SEQ ID NO: 78) were used in a secondary amplification using 10% of the primary amplification as template cDNA. PCRs were carried out using the GeneAmp DNA Amplification kit (Perkin Elmer, Norwalk, CT)

using a programmable thermal controller from MJ Research, Inc. (Cambridge, MA). Samples were amplified for 24 cycles by heating to 94°C for 1 min, 54°C for 1.5 min and 70°C for 1 min.

The resulting PCR product was blunted with T4 DNA polymerase (Sambrook *et al.* (1989) *supra*) and digested with the restriction endonuclease *Xba*I. Unless otherwise stated, all endonucleases and polymerases were obtained from New England BioLabs (Beverly, MA). A band of approximately 400 base pairs was isolated from a low melting temperature agarose gel (FMC, Rockland, ME) and ligated into appropriately digested pUC19. The clones 22.2 and 22.5 were subsequently identified by dideoxysequencing (Sanger *et al.* (1977), *Proc. Natl. Acad. Sci. USA*, 74:5460-5463) to contain nucleotide sequence of the gene encoding *Dac g 1*.

A 600 base pair cDNA containing internal nucleotide sequence of the gene encoding *Dac g 1* was amplified using the primers DGI-3 (5'-TTGGATCCTACGGCAAGCCGACCGGC-3') (SEQ ID NO: 84) and LpA-10 (5'-CCGTCGACGTACTTCA-3') (SEQ ID NO: 81). A 300 base pair cDNA containing internal *Dac g 1* sequence was amplified using the primers DGI-4 (5'-TTGGATCCATCCCGAAGGTGCCCCCGGG-3' (SEQ ID NO: 85), wherein G at position 14 can also be A) and LpA-9 (5'-GTGACAGCCTCGCCGG-3') (SEQ ID NO: 78). The cDNAs were amplified for 34 cycles by heating to 94°C for 45 sec, 60°C for 45 sec and 72°C for 1 min. These PCR products were blunted with T4 DNA polymerase as above, digested with *Bam*HI and ligated into appropriately digested pUC19. Clones 86.1 (600 base pairs) and 88.6 (300 base pairs) were sequenced and found to contain sequence of the gene encoding *Dac g 1*.

The carboxy portion of the gene encoding *Dac g 1*, including the 3' untranslated region, was cloned using oligonucleotide primers AP (5'-GGGTCTAGAGGTACCGTCCG-3') (SEQ ID NO: 73) and DGI-8 (5'-AGGTGACCTTCCACGTCG-3') (SEQ ID NO: 86) in a primary PCR and oligonucleotide primers AP and DGI-9 (5'-TTGGATCCTGGCGCTGCTGGTGAAGTA-3') (SEQ ID NO: 87) in a secondary PCR. Material was amplified for 25 cycles of heating to 94°C for 1 min, 60°C for 40 sec and 74°C for 1 min. The 700 base pair PCR product was digested with *Bam*HI and *Asp*718 (Boehringer Mannheim, Indianapolis, IN), isolated and digested into appropriately digested pUC19 as described above. The clones 119.2, 119.4, 119.6, 119.9 and 119.12 were isolated, sequenced and found to contain sequence of the gene encoding *Dac g 1*.

2157596

cDNA clones encoding the mature *Dac g 1* protein were obtained by PCR with the oligonucleotide primers DGI-7Eco (5'-TTGAATTCATCCCGAAGGTGCCCCCG-3' (SEQ ID NO: 88), wherein G at position 14 can also be A) and Pha-1.2 (5'-TTGGTACCTCACTTGGACTCGTAGCT-3') (SEQ ID NO: 89). The cDNAs were amplified for 24 cycles of heating to 94°C for 1 min, 54°C for 1.5 min and 70°C for 1 min. The amplified cDNA was digested with *EcoRI* and *Asp718*, isolated, and ligated into the appropriately digested pUC19. The cDNA clones 106.5, 106.6, 106.9 and 106.12 were identified as containing *Dac g 1* sequence by dideoxysequencing. The nucleotide (SEQ ID NO: 51) and deduced amino acid (SEQ ID NO: 52) sequences of clone 106.5 are shown in Fig. 5. Nucleotides 509-515 (encoding amino acids 171 and 172) are from the sequence of clone 106.12. The sequence of clone 106.5 was not resolved in this region.

The insert from clone 106.5 was isolated and ligated into appropriately digested expression vector pET-11d (Novagen, Madison, WI: Jameel et al. (1990), *J. Virol.*, 64:3963-3966). The pET-11d vector had been modified to contain a sequence encoding 6 histidines (His 6) immediately 3' of the ATG initiation codon followed by a unique *EcoRI* endonuclease restriction site. A second *EcoRI* endonuclease restriction site in the vector, along with neighboring *ClaI* and *HindIII* endonuclease-restriction sites, had previously been removed by digestion with *EcoRI* and *HindIII*, blunted and religated.

A recombinant clone was used to transform *Escherichia coli* strain BL21-DE3. A culture was grown to A<sub>600</sub> of 1.0, IPTG was added to 1 mM final concentration and grown for an additional 2 hours. Bacteria was recovered by centrifugation (7,930 G, 10 min) and lysed in 90 ml of 6 M Guanidine-HCl, 0.1 M Na<sub>2</sub>HPO<sub>4</sub>, pH 8.0 for 1 hour with vigorous shaking. The recombinant *Dac g 1* was purified from the extract on a Ni<sup>+2</sup> chelating column (Hochuli et al. (1987) *J. Chromatog.*, 411:177-184; Hochuli et al. (1988), *Bio/Tech.*, 6:1321-1325).

### 30 B. Cloning of *Poa p I*.

RNA was isolated from the pollen of *Poa pratensis*, double stranded cDNA was prepared and self-annealed oligonucleotides AT and AL were added as described in section A, above. PCR product was amplified using oligonucleotide primers PhI-7 (5'-CCGAATTCGTGGAGAAGGGGTCCAA-3') (SEQ ID NO: 90) and Poa-1 (5'-TTAGGATCCTCACTTATCATAIGACGTATC-3' (SEQ ID NO: 91), wherein C at



position 13 can also be T, A at position 16 can also be G, A at position 19 can also be G, G at position 23 can also be C, A at position 24 can also be T, C at position 25 can also be T or A or G and A at position 28 can be G). All *Poa p 1* clones were amplified by 20 cycles of heating to 94°C for 1 min, 55°C for 1 min and 72°C for 1 min. The amplified material was finally heated to 72°C for 5 min. Three clones, 11, 15 and 17, were isolated that contained part of the nucleotide sequence for the gene that encodes *Poa p 1*. The *Dac g 1* sequence encoded by clones 11, 15 and 17 corresponds to amino acids 151 - 240 of Fig. 6.

Clones containing partial nucleotide sequences of the gene encoding *Poa p 1* were derived from PCRs that used oligonucleotide primers AP and Poa-3 (5'-TTGAATTCCTTGTCATTGCCCTTCTG-3') (SEQ ID NO: 92) in the primary PCR and AP and Poa-4 (5'-AAGAATTCCTTCTGCTTGATGTCCAC-3') (SEQ ID NO: 93) in the secondary PCR. Other clones were derived from PCRs that used oligonucleotide primers AP and Poa-6 (5'-ATGAATTCGAGTCGTGGGGAGCCGTC-3') (SEQ ID NO: 94) in the primary PCR and AP and Poa-7 (5'-ATGAATTCGTCTGGAGGATCGACACC-3') (SEQ ID NO: 95) in the secondary PCR. Clones 58, 59 and 63 were derived from the PCR using primers AP and Poa-4. Clones 91 and 97 were derived from the PCR using primers AP and Poa-7.

Additional clones were derived from a PCR that used oligonucleotide primers Poa-1 and Poa-5 (5'-ATGAATTCATCGCAAAGGTTCCCCC-3' (SEQ ID NO: 96), wherein A at position 14 can also be G or C or T). These clones, 113, 114 and 115, corresponded to the portion of the gene that encoded amino acids 1 - 240 of *Poa p 1* (see Fig. 6). The nucleotide (SEQ ID NO: 53) and deduced amino acid (SEQ ID NO: 54) sequences of clone 114 are shown in Fig. 6. Nucleotide 93 in Fig. 6 was not resolved and could be a G or a C or a T or an A and is represented by the letter "N". Nucleotide 94 in Fig. 6 was not conclusively resolved and could be a G or a C or a T but not an A and is represented by the letter "B". The codon containing nucleotide 93 (GGN) encodes a Glycine at residue 31. The codon containing nucleotide 94 (BCC) encodes an Alanine (GCC), a Proline (CCC), or a Serine (TCC) at amino acid 32. The amino acid at residue 32 in Fig. 6 is represented by an "X".

Inserts from clones 11 and 114 were isolated and ligated into appropriately digested expression vector pET-11d (Novagen, Madison, WI: Jameel et al. (1990) *J. Virol.* 64:3963-3966). Recombinant proteins were expressed as described in section A, above.

2157596

### C. Cloning of *Phl p 1*.

RNA was isolated from the pollen of *Phleum pratense*, double stranded cDNA was prepared and self-annealed oligonucleotides AT and AL were added as described in section A, above. Clones were derived from a PCR that used oligonucleotide primers PhA1.1 (5'-TTTGGATCCTCACTTGGACTCGTAGCT-3') (SEQ ID NO: 97) and PhI-2 (5'-TTGAATTCTCGCGAAGGTGCCCCCG-3') (SEQ ID NO: 98), wherein G at position 13 can also be A). These clones, 20 and 22, corresponded to the portion of the gene that encoded amino acids 1 - 240 of *Phl p 1* (see Fig. 7). The nucleotide (SEQ ID NO: 55) and deduced amino acid (SEQ ID NO: 56) sequences of clone 20 are shown in Fig. 7.

Clones containing partial nucleotide sequence of the gene encoding *Phl p 1* were derived from a PCR using oligonucleotide primers PhI-7 (5'-CCGAATTCGTGGAGAAGGGGTCCAA-3') (SEQ ID NO: 90) and PhA1.1. Clones 47-52 were derived from this PCR. These clones encoded amino acids 151 through 240 of Fig. 7.

Inserts from clones 22 and 51 were isolated and ligated into appropriately digested expression vector pET-11d (Novagen, Madison, WI: Jameel et al. (1990) *J. Virol.* 64:3963-3966). Recombinant proteins were expressed as described in section A, above.

### Example 6 - Comparison of *Dac g 1*, *Phl p 1* and *Poa p 1* With *Lol p 1*.

The sequences for *Dac g 1* (Fig. 5) (SEQ ID NO: 58), *Phl p 1* (Fig. 7) (SEQ ID NO: 59) and *Poa p 1* (Fig. 6) (SEQ ID NO: 60) were compared with *Lol p 1* (SEQ ID NO: 57). The amino acid sequences of these Group 1 allergens had 95% (*Dac g 1*), 91% (*Phl p 1*) and 91% (*Poa p 1*) identity, respectively, with *Lol p 1*. This comparison is shown schematically in Fig. 8. The complete sequence of *Lol p 1* is shown in standard one letter code. Only differences from the *Lol p 1* sequence are shown for the other Group 1 allergens; identity is indicated by a dash (-). Potential amino acid polymorphisms were predicted by detected nucleotide polymorphisms in each sequence. Such potential polymorphisms are shown by superscript and subscript letters at the site of the polymorphism.

T cell epitope containing peptides of *Lol p 1*, peptides 16.1 (SEQ ID NO: 23), 18 (SEQ ID NO: 25), 20 (SEQ ID NO: 27) and 23 (SEQ ID NO: 30), were defined in

Example 4 (Fig. 3). The sequences of the other Group 1 allergens are very conserved in these regions. Since the Group 1 allergens are homologous, the major T cell epitope containing peptides of *Lol p 1* are likely to be the major T cell epitope containing regions in the related grasses. Comparison of the sequences of the *Lol p 1* peptides with the homologous peptides containing *Dac g 1*, *Phl p 1* and *Poa p 1* polymorphisms are shown in Fig. 9 (SEQ ID NO: 23, 25, 27, 30, 61-70).

## SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- 5 (i) APPLICANT:
- (A) NAME: IMMULOGIC PHARMACEUTICAL CORPORATION  
(B) STREET: 610 LINCOLN STREET  
(C) CITY: WALTHAM  
10 (D) STATE: MASSACHUSETTS  
(E) COUNTRY: USA  
(F) POSTAL CODE (ZIP): 02154  
(G) TELEPHONE: (617) 466-6000  
(H) TELEFAX: (617) 466-6010
- 15 (ii) TITLE OF INVENTION: T CELL EPITOPES OF RYEGRASS POLLEN ALLERGENS
- (iii) NUMBER OF SEQUENCES: 98
- 20 (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: LAHIVE & COCKFIELD  
(B) STREET: 60 State Street, suite # 510  
(C) CITY: Boston  
25 (D) STATE: Massachusetts  
(E) COUNTRY: US  
(F) ZIP: 02109-1875
- 30 (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: ASCII text
- 
- 35 (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:
- 40 (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: US 08/106,016  
(B) FILING DATE: 31-AUG-1993
- (vii) PRIOR APPLICATION DATA:
- 45 (A) APPLICATION NUMBER: US 08/031,001  
(B) FILING DATE: 12-MAR-1993
- (viii) ATTORNEY/AGENT INFORMATION:
- 50 (A) NAME: Amy E. Mandragouras  
(B) REGISTRATION NUMBER: 36,207  
(C) REFERENCE/DOCKET NUMBER: (IMI-040PC)
- (ix) TELECOMMUNICATION INFORMATION:
- 55 (A) TELEPHONE: (617) 227-7400  
(B) TELEFAX: (617) 227-5941
- (2) INFORMATION FOR SEQ ID NO:1:
- 60 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1124 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(11) MOLECULE TYPE: cDNA

5 (1x) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 16..804

10 (1x) FEATURE:  
 (A) NAME/KEY: mat\_peptide  
 (B) LOCATION: 85..804

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

15 CAAATTCAAG ACAAG ATG GCG TCC TCC TCG TCG GTG CTC CTG GTG GTG GCG  
 51 Met Ala Ser Ser Ser Ser Val Leu Leu Val Val Ala  
 -23 -20 -15

20 CTG TTC GCC GTG TTC CTG GGC AGC GCG CAT GGC ATC GCG AAG GTA CCA  
 99 Leu Phe Ala Val Phe Leu Gly Ser Ala His Gly Ile Ala Lys Val Pro  
 -10 -5 1 5

25 CCG GGC CCC AAC ATC ACG GCC GAG TAC GGC GAC AAG TGG CTG GAC GCG  
 147 Pro Gly Pro Asn Ile Thr Ala Glu Tyr Gly Asp Lys Trp Leu Asp Ala  
 10 15 20

30 AAG AGC ACC TGG TAT GGC AAG CCG ACC GGC GCC GGT CCC AAG GAC AAC  
 195 Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp Asn  
 25 30 35

35 GGC GGC GCG TGC GGG TAC AAG GAC GTT GAC AAG GCG CCG TTC AAC GGC  
 243 Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys Ala Pro Phe Asn Gly  
 40 45 50

40 ATG ACC GGC TGC GGC AAC ACC CCC ATC TTC AAG GAC GGC CGT GGC TGC  
 291 Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys Asp Gly Arg Gly Cys  
 55 60 65

45 GGC TCC TGC TTC GAG ATC AAG TGC ACC AAG CCC GAG TCC TGC TCC GGC  
 339 Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro Glu Ser Cys Ser Gly  
 70 75 80 85

50 GAG GCT GTC ACC GTC ACA ATC ACC GAC GAC AAC GAG GAG CCC ATC GCA  
 387 Glu Ala Val Thr Val Thr Ile Thr Asp Asp Asn Glu Glu Pro Ile Ala  
 90 95 100

55 CCC TAC CAT TTC GAC CTC TCG GGC CAC GCG TTC GGG TCC ATG GCG AAG  
 435 Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ser Met Ala Lys  
 105 110 115

60 AAG GGC GAG GAG CAG AAG CTC CGC AGC GCC GGC GAG CTG GAG CTC CAG  
 483 Lys Gly Glu Glu Gln Lys Leu Arg Ser Ala Gly Glu Leu Glu Leu Gln  
 120 125 130

2157596

5 TTC AGG CCG GTC AAG TGC AAG TAC CCG GAC GGC ACC AAG CCG ACA TTC  
 531  
 Phe Arg Arg Val Lys Cys Lys Tyr Pro Asp Gly Thr Lys Pro Thr Phe  
 135 140 145  
 10 CAC GTC GAG AAG GCT TCC AAC CCC AAC TAC CTC GCT ATT CTG GTG AAG  
 579  
 His Val Glu Lys Ala Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys  
 150 155 160 165  
 15 TAC GTC GAC GGC GAC GGT GAC GTG GTG GCG GTG GAC ATC AAG GAG AAG  
 627  
 Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys  
 170 175 180  
 20 GGC AAG GAT AAG TGG ATC GAG CTC AAG GAG TCG TGG GGA GCA GTC TGG  
 675  
 Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala Val Trp  
 185 190 195  
 25 AGG ATC GAC ACC CCC GAT AAG CTG ACG GGC CCA TTC ACC GTC CGC TAC  
 723  
 Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro Phe Thr Val Arg Tyr  
 200 205 210  
 30 ACC ACC GAG GGC GGC ACC AAA TCC GAA GTC GAG GAT GTC ATC CCT GAG  
 771  
 Thr Thr Glu Gly Gly Thr Lys Ser Glu Val Glu Asp Val Ile Pro Glu  
 215 220 225  
 GGC TGG AAG GCC GAC ACC TCC TAC TCG GCC AAG TGAGCAAGAA GTGGAGTGAT  
 824  
 35 Gly Trp Lys Ala Asp Thr Ser Tyr Ser Ala Lys  
 230 235 240  
 CTCTTTCCAA TCAGCTTAAT TTTGACTCAA GATCTCAAAT AATCCAGCCG CACATATATA  
 884  
 40 CGAGGCGGTG AGACATACAA GCTCCTCCAT GAGTATATTC ATTCATGCCG TATAGAGAGG  
 944  
 AGAAAGATGC CTGAATAAGA GTTTGAGGTC GACACCTTGT GAGAAGTGTA TATAGGAGGA  
 1004  
 45 ACCCAATCTG GCTCCATCTT TCTTTGCTCG CACGGGTGTAC TGCTAAGGTT ATCTTCTAAC  
 1064  
 50 AGGCCAGATT AACCTACTAT CTAATATATG CAACGTATGG TCATTTTCCC TAAAAAAAAA  
 1124

## (2) INFORMATION FOR SEQ ID NO:2:

55 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 263 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

60 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Ser Ser Ser Ser Val Leu Leu Val Val Ala Leu Phe Ala Val

[illegible]

## (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Glu Tyr Gly Asp  
 1 5 10 15

Lys Trp Leu Asp  
 20

## (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Ile Ala Lys Val Xaa Pro Gly Xaa Asn Ile Thr Ala Glu Tyr Gly Asp  
 1 5 10 15

Lys Trp Leu Asp  
 20

## (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Thr Ala Glu Tyr Gly Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr  
 1 5 10 15

Gly Lys Pro Thr  
 20

## (2) INFORMATION FOR SEQ ID NO:6:



(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:  
Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp  
1 5 10 15  
Asn Gly Gly Ala  
20

20 (2) INFORMATION FOR SEQ ID NO:7:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:  
Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asn Val  
1 5 10 15  
Asp Lys Ala Pro  
20

40 (2) INFORMATION FOR SEQ ID NO:8:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:  
Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val  
1 5 10 15  
Asp Lys Ala Pro  
20

60 (2) INFORMATION FOR SEQ ID NO:9:  
(i) SEQUENCE CHARACTERISTICS:

2157596

(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
Cys Gly Tyr Lys Asp Val Asp Lys Ala Pro Phe Asn Gly Met Thr Gly  
1 5 10 15  
15 Cys Gly Asn Thr  
20

20 (2) INFORMATION FOR SEQ ID NO:10:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
Phe Asn Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys Asp Gly  
1 5 10 15  
35

Arg Gly Cys Gly  
20

5 (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

20 Pro Ile Phe Lys Asp Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys  
1 5 10 15  
Cys Thr Lys Pro  
20

25 (2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

40 Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro Glu Ser Cys Ser Gly Glu  
1 5 10 15  
Ala Val Thr Val  
20

45

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: peptide

55

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

60

Glu Ser Cys Ser Gly Glu Ala Val Thr Val Thr Ile Thr Asp Asp Asn  
1 5 10 15  
Glu Glu Pro Ile

2157596

20

## (2) INFORMATION FOR SEQ ID NO:14:

- 5 (1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal
- 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:  
 Thr Ile Thr Asp Asp Asn Glu Glu Pro Ile Ala Pro Tyr His Phe Asp  
 1 5 10 15  
 20 Leu Ser Gly His  
 20

## (2) INFORMATION FOR SEQ ID NO:15:

- 25 (1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear
- 30 (ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal
- 
- 35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:  
 Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ser Met Ala  
 1 5 10 15  
 40 Asp Asp Gly Glu  
 20

2157596

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

- 10 (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

- 15 Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ser Met Ala  
1 5 10 15  
20 Lys Lys Gly Glu  
20

## (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

- 30 (v) FRAGMENT TYPE: internal

---

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

- Ala Phe Gly Ser Met Ala Asp Asp Gly Glu Glu Gln Lys Leu Arg Ser  
1 5 10 15  
40 Ala Gly Glu Leu  
20

## (2) INFORMATION FOR SEQ ID NO:18:

## (i) SEQUENCE CHARACTERISTICS:

- 45 (A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## 50 (ii) MOLECULE TYPE: peptide

- (v) FRAGMENT TYPE: internal

55

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

- Ala Phe Gly Ser Met Ala Lys Lys Gly Glu Glu Gln Lys Leu Arg Ser  
1 5 10 15  
60 Ala Gly Glu Leu  
20

## (2) INFORMATION FOR SEQ ID NO:19:

2157596

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
- Glu Gln Lys Leu Arg Ser Ala Gly Glu Leu Glu Leu Gln Phe Arg Arg  
 1 5 10 15  
 Val Lys Cys Lys  
 20
- (2) INFORMATION FOR SEQ ID NO:20:
- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal
- 
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
- Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Asp Asp Thr Lys  
 1 5 10 15  
 Pro Thr Phe His  
 20
- (2) INFORMATION FOR SEQ ID NO:21:
- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
- Tyr Pro Asp Asp Thr Lys Pro Thr Phe His Val Glu Lys Ala Ser Asn  
 1 5 10 15  
 Pro Asn Tyr Leu  
 20
- (2) INFORMATION FOR SEQ ID NO:22:

(1) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 20 amino acids  
    (B) TYPE: amino acid  
    (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide  
    (v) FRAGMENT TYPE: internal

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:  
Val Glu Lys Ala Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr  
15 1 5 10 15  
Val Asp Gly Asp  
20 20

20 (2) INFORMATION FOR SEQ ID NO:23:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 20 amino acids  
        (B) TYPE: amino acid  
25 (D) TOPOLOGY: linear  
    (ii) MOLECULE TYPE: peptide  
    (v) FRAGMENT TYPE: internal

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:  
Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr  
35 1 5 10 15  
Val Asp Gly Asp  
40 20

(2) INFORMATION FOR SEQ ID NO:24:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 20 amino acids  
45 (B) TYPE: amino acid  
        (D) TOPOLOGY: linear  
    (ii) MOLECULE TYPE: peptide  
50 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:  
Ala Ile Leu Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val  
55 1 5 10 15  
Asp Ile Lys Glu  
60 20

(2) INFORMATION FOR SEQ ID NO:25:  
    (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

- 5 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

- 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp  
1 5 10 15  
Ile Glu Leu Lys  
20

- 20 (2) INFORMATION FOR SEQ ID NO:26:  
(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

- 25 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala Val  
1 5 10 15  
Trp Arg Ile Asp  
20

- 40 (2) INFORMATION FOR SEQ ID NO:27:  
(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

- 45 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

- 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Glu Ser Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr  
1 5 10 15  
Gly Pro Phe Thr  
20

- 60 (2) INFORMATION FOR SEQ ID NO:28:  
(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids



(B) TYPE: amino acid  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Thr Pro Asp Lys Leu Thr Gly Pro Phe Thr Val Arg Tyr Thr Thr Glu  
1 5 10 15

15 Gly Gly Thr Lys  
20

2157596

## (2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Val Arg Tyr Thr Glu Gly Gly Thr Lys Ser Glu Val Glu Asp Val  
1 5 10 15  
Ile Pro Glu Gly  
20

## (2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser  
1 5 10 15  
Tyr Ser Ala Lys  
20

## (2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Asp Glu Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val  
1 5 10 15  
Lys Tyr Val Asp Gly Asp  
20

## (2) INFORMATION FOR SEQ ID NO:32:

2157596

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:  
Asp Glu Ala Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val  
1 5 10 15  
Lys Tyr Val Asp Gly Asp  
20
- (2) INFORMATION FOR SEQ ID NO:33:  
(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal
- 
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:  
Lys Lys Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val  
1 5 10 15  
Lys Lys
- (2) INFORMATION FOR SEQ ID NO:34:  
(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:  
Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Asp Glu  
1 5 10 15
- (2) INFORMATION FOR SEQ ID NO:35:  
(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- 5 (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
- 10 Ala Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Asp Glu  
1 5 10 15
- (2) INFORMATION FOR SEQ ID NO:36:
- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear
- 20 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal
- 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
- 30 Asp Glu Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Asp Glu  
1 5 10 15
- 
- (2) INFORMATION FOR SEQ ID NO:37:
- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear
- 40 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal
- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
- Lys Lys Ala Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Ile Leu Val  
1 5 10 15
- 50 Lys Lys
- (2) INFORMATION FOR SEQ ID NO:38:
- 55 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear
- 60 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:38:

5      Asp Glu Pro Asn Tyr Leu Ala Ile Leu Val Lys Tyr Val Asp Glu  
      1                            5                            10                            15

(2) INFORMATION FOR SEQ ID NO:39:

10      (i) SEQUENCE CHARACTERISTICS:  
          (A) LENGTH: 15 amino acids  
          (B) TYPE: amino acid  
          (D) TOPOLOGY: linear

15      (ii) MOLECULE TYPE: peptide  
          (v) FRAGMENT TYPE: internal

20      (x1) SEQUENCE DESCRIPTION: SEQ ID NO:39:

25      Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys  
          1                            5                            10                            15

## (2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Glu  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Glu Leu  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 14 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:43:

5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

15 Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr  
1 5 10

20 (2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

---

35 Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly  
1 5 10

(2) INFORMATION FOR SEQ ID NO:45:

40 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro Phe Thr  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Glu Ser Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Ala Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr  
1 5 10 15



## (2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser Tyr Ser  
1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser Tyr Ser Ala Lys  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 723 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS  
(B) LOCATION: 1..720

2157596

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:51:

ATC CCG AAG GTG CCC CCG GGC CCG AAC ATC ACG GCG ACC TAC GGT GAC  
 48  
 5 Ile Pro Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 15  
 AAG TGG CTG GAC GCG AAG AGC ACA TGG TAC GGC AAG CCG ACG GGC GCC  
 96  
 10 Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala  
 20 25 30  
 GGC CCC AAG GAC AAC GGC GGC GCG TGC GGC TAC AAG GAC GTG GAC AAG  
 144  
 15 Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45  
 GCG CCG TTC AAC GGC ATG ACC GGG TGC GGC AAC ACC CCC ATC TTC AAG  
 192  
 20 Ala Pro Phe Asn Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60  
 GAC GGG CGC GGG TGC GGT TCC TGC TTC GAG ATC AAG TGC ACG AAG CCC  
 240  
 25 Asp Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80  
 GAG TCG TGC TCC GGC GAG GCC GTC ACC GTC CAC ATC ACC GAC GAC AAC  
 288  
 30 Glu Ser Cys Ser Gly Glu Ala Val Thr Val His Ile Thr Asp Asp Asn  
 85 90 95  
 GAG GAG CCC ATC GCG CCC TAC CAC TTC GAC CTT TCC GGC CAC GCG TTC  
 336  
 35 Glu Glu Pro Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe  
 100 105 110  
 GGT TCC ATG GCG AAG AAG GGC GAG GAG CAG AAG CTG CGC AGC GCG GGC  
 384  
 40 Gly Ser Met Ala Lys Lys Gly Glu Glu Gln Lys Leu Arg Ser Ala Gly  
 115 120 125  
 GAG CTG GAG CTG CAG TTT AGG CGG GTG AAG TGC AAG TAC CCC GAG GGC  
 432  
 45 Glu Leu Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Glu Gly  
 130 135 140  
 ACC AAG GTG ACC TTC CAC GTC GAG AAG GGT TCC AAC CCC AAC TAC CTG  
 480  
 50 Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu  
 145 150 155 160  
 GCG CTG CTG GTG AAG TAC GTC GAC GGC GAC GGC GAC GTG GTG GCG GTG  
 528  
 55 Ala Leu Leu Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val  
 165 170 175  
 GAT ATC AAG GAG AAG GGC AAG GAC AAG TGG ATC GCG CTC AAG GAG TCA  
 576  
 60 Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Ala Leu Lys Glu Ser  
 180 185 190  
 TGG GGA GCC ATC TGG AGG GTG GAC ACC CCC GAC AAG CTG ACG GGC CCA  
 624

WO 94/21675

PCT/US94/02537

2157596

Trp Gly Ala Ile Trp Arg Val Asp Thr Pro Asp Lys Leu Thr Gly Pro  
195 200 205

---

2157596

TTC ACC GTT CGC TAC ACC ACC GAG GGA GGC ACC AAG TCC GAA GTT GAG  
 672  
 Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ser Glu Val Glu  
 210 215 220  
 5 GAC GTC ATC CCC GAG GGC TGG AAG GCC GAC GCC AGC TAC GAG TCC AAG  
 720  
 Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Ala Ser Tyr Glu Ser Lys  
 225 230 235 240  
 10 TGA  
 723

(2) INFORMATION FOR SEQ ID NO:52:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 240 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Ile Pro Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 10 15  
 30 Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala  
 20 25 30  
 Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45  
 35 Ala Pro Phe Asn Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60  
 40 Asp Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80  
 Glu Ser Cys Ser Gly Glu Ala Val Thr Val His Ile Thr Asp Asp Asn  
 85 90 95  
 45 Glu Glu Pro Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe  
 100 105 110  
 Gly Ser Met Ala Lys Lys Gly Glu Glu Gln Lys Leu Arg Ser Ala Gly  
 115 120 125  
 50 Glu Leu Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Glu Gly  
 130 135 140  
 55 Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu  
 145 150 155 160  
 Ala Leu Leu Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val  
 165 170 175  
 60 Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Ala Leu Lys Glu Ser  
 180 185 190  
 Trp Gly Ala Ile Trp Arg Val Asp Thr Pro Asp Lys Leu Thr Gly Pro  
 195 200 205

2157596

Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ser Glu Val Glu  
 210 215 220

5 Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Ala Ser Tyr Glu Ser Lys  
 225 230 235 240

## (2) INFORMATION FOR SEQ ID NO:53:

10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 723 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

20 (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 1..720

(ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 32  
 (D) OTHER INFORMATION: /note= "Xaa is Ser, Pro or Ala"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

ATC GCG AAG GTT CCC CCC GGC CCG AAC ATC ACG GCG ACC TAC GGC GAC  
 48  
 Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 10 15

---

35 AAG TGG CTT GAC GCG AAG AGC ACC TGG TAC GGC AAG CCG ACC GGN BCC  
 96  
 Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Xaa  
 20 25 30

40 GGT CCC AAG GAC AAC GGC GGC GCG TGC GGA TAC AAG GAC GTG GAC AAG  
 144  
 Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45

45 CCC CCG TTC AGC GGC ATG ACC GGC TGC GGC AAC ACC CCC ATC TTC AAG  
 192  
 Pro Pro Phe Ser Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60

50 TCC GGC CGC GGC TGC GGC TCC TGC TTC GAG ATC AAG TGC ACC AAG CCC  
 240  
 Ser Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80

55 GAG TCC TGC TCC GGC GAG CCC GTC CTG GTC CAC ATC ACC GAC GAC AAC  
 288  
 Glu Ser Cys Ser Gly Glu Pro Val Leu Val His Ile Thr Asp Asp Asn  
 85 90 95

60 GAG GAG CCC ATC GCC GCC TAC CAC TTC GAC CTC TCC GGC AAG GCG TTC  
 336  
 Glu Glu Pro Ile Ala Ala Tyr His Phe Asp Leu Ser Gly Lys Ala Phe  
 100 105 110

2157596

5 GGG GCC ATG GCC AAG AAG GGT GAG GAG CAG AAG CTG CGC AGC GCC GGC  
 384  
 Gly Ala Met Ala Lys Lys Gly Glu Glu Gln Lys Leu Arg Ser Ala Gly  
 115 120 125  
 10 GAG CTG GAG CTC AAG TTC CGC CGC GTC AAG TGC GAG TAC CCG AAG GGC  
 432  
 Glu Leu Glu Leu Lys Phe Arg Arg Val Lys Cys Glu Tyr Pro Lys Gly  
 130 135 140  
 15 ACC AAG GTT ACC TTC CAC GTC GAG AAG GGG TCC AAC CCC AAC TAC CTT  
 480  
 Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu  
 145 150 155 160  
 20 GCG CTG CTG GTG AAG TAC GTC GAC GGC GAC GGG GAC GTG GTG GCG GTG  
 528  
 Ala Leu Leu Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val  
 165 170 175  
 25 GAC ATC AAG CAG AAG GGC AAG GAC AAG TGG ATC GAG CTC AAG GAG TCG  
 576  
 Asp Ile Lys Gln Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser  
 180 185 190  
 30 TGG GGA GCC GTC TGG AGG ATC GAC ACC CCC GAC AAG CTC ACC GGC CCC  
 624  
 Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro  
 195 200 205  
 35 TTC ACC GTC CGC TAC ACC ACC GAG GGC GGC ACC AAG GCC GAA GCC GAG  
 672  
~~Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ala Glu Ala Glu~~  
~~210 215 220~~  
 40 GAC GTC ATC CCC GAG GGC TGG AAG GCC GAC ACC GCC TAC GAG GCC AAG  
 720  
 Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ala Tyr Glu Ala Lys  
 225 230 235 240  
 TGA  
 723

45 (2) INFORMATION FOR SEQ ID NO:54:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 240 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: protein

55

## (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 32

(D) OTHER INFORMATION: /note= "Xaa is Ser, Pro or Ala"

5

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

1 Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 10 15  
 10 Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Xaa  
 20 25 30  
 15 Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45  
 Pro Pro Phe Ser Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60  
 20 Ser Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80  
 Glu Ser Cys Ser Gly Glu Pro Val Leu Val His Ile Thr Asp Asp Asn  
 85 90 95  
 25 Glu Glu Pro Ile Ala Ala Tyr His Phe Asp Leu Ser Gly Lys Ala Phe  
 100 105 110  
 Gly Ala Met Ala Lys Lys Gly Glu Glu Gln Lys Leu Arg Ser Ala Gly  
 115 120 125  
 30 Glu Leu Glu Leu Lys Phe Arg Arg Val Lys Cys Glu Tyr Pro Lys Gly  
 130 135 140

---

35 Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu  
 145 150 155 160  
 Ala Leu Leu Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val  
 165 170 175  
 40 Asp Ile Lys Gln Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser  
 180 185 190  
 Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro  
 195 200 205  
 45 Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ala Glu Ala Glu  
 210 215 220  
 50 Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ala Tyr Glu Ala Lys  
 225 230 235 240

## (2) INFORMATION FOR SEQ ID NO:55:

- (1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 723 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(11) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 1..720

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

ATC GCG AAG GTG CCC CCG GGT CCG AAC ATC ACG GCG ACC TAC GGC GAC  
 48  
 Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 10 15

AAG TGG CTC GAC GCG AAG AGC ACA TGG TAC GGC AAG CCG ACG GGG GCC  
 96  
 Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala  
 20 25 30

GGT CCC AAG GAC AAC GGC GGC GCT TGC GGG TAC AAG GAC GTG GAC AAG  
 144  
 Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45

---

CCC CCG TTC AGC GGC ATG ACC GGC TGC GGC AAC ACC CCG ATC TTC AAG  
 192  
 Pro Pro Phe Ser Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60

TCC GGC CGT GGC TGC GGC TCC TGC TTT GAG ATC AAG TGC ACG AAG CCC  
 240  
 Ser Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80

GAG GCC TGC TCC GGC GAG CCC GTG GTA GTC CAC ATC ACC GAC GAC AAC  
 288  
 Glu Ala Cys Ser Gly Glu Pro Val Val Val His Ile Thr Asp Asp Asn  
 85 90 95

GAG GAG CCC ATC GCC CCC TAC CAC TTC GAC CTC TCC GGC CAC GCG TTC  
 336  
 Glu Glu Pro Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe  
 100 105 110

GGG GCG ATG GCC AAG AAG GGC GAT GAG CAG AAG CTG CGC ACG GCC GGC  
 384  
 Gly Ala Met Ala Lys Lys Gly Asp Glu Gln Lys Leu Arg Thr Ala Gly  
 115 120 125

GAG CTG GAG CTC CAG TTC CGG CGC GTC AAG TGC AAG TAC CCG GAG GGC  
 432  
 Glu Leu Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Glu Gly  
 130 135 140



```

ACC AAG GTG ACC TTC CAC GTG GAG AAG GGG TCC AAC CCC AAC TAC CTG
480
Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu
145          150          155          160

5  GCG CTG CTT GTG AAG TAC GTT AAC GGC GAC GGA GAC GTG GTG GCG GTG
528
Ala Leu Leu Val Lys Tyr Val Asn Gly Asp Gly Asp Val Val Ala Val
          165          170          175

10 GAC ATC AAG GAG AAG GGC AAG GAC AAG TGG ATC GAG CTC AAG GAG TCG
576
Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser
          180          185          190

15 TGG GGA GCC ATC TGG AGG ATC GAC ACT CCC GAC AAG CTC ACG GGC CCC
624
Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro
          195          200          205

20 TTC ACC GTC CGC TAC ACC ACC GAG GGC GGC ACC AAG ACC GAA GCC GAG
672
Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Thr Glu Ala Glu
          210          215          220

25 GAC GTC ATC CCT GAG GGC TGG AAG GCC GAC ACC AGC TAC GAG TCC AAG
720
Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser Tyr Glu Ser Lys
225          230          235          240

30 TGA
723

```

## 35 (2) INFORMATION FOR SEQ ID NO:56:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 240 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

40

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

45

Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 10 15

50

Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala  
 20 25 30

Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45

55

Pro Pro Phe Ser Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60

Ser Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80

60

Glu Ala Cys Ser Gly Glu Pro Val Val Val His Ile Thr Asp Asp Asn  
 85 90 95

Glu Glu Pro Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe

100 105

Gly Ala Met Ala Lys Lys Gly Asp Glu Gln Lys Leu Arg Thr Ala Gly  
115 120 125

5 Glu Leu Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Glu Gly  
130 135 140

10 Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu  
145 150 155 160

Ala Leu Leu Val Lys Tyr Val Asn Gly Asp Gly Asp Val Val Ala Val  
165 170 175

15 Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser  
180 185 190

Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro  
195 200 205

20 Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Thr Glu Ala Glu  
210 215 220

25 Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser Tyr Glu Ser Lys  
225 230 235 240

## (2) INFORMATION FOR SEQ ID NO:57:

- 30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 240 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear
- 
- 35 (ii) MOLECULE TYPE: peptide  
(v) FRAGMENT TYPE: internal
- 40 (ix) FEATURE:  
(A) NAME/KEY:  
(B) LOCATION: 45  
(D) OTHER INFORMATION: /note= "Xaa is Asn or Asp"
- 45 (ix) FEATURE:  
(A) NAME/KEY:  
(B) LOCATION: 144  
(D) OTHER INFORMATION: /note= "Xaa is Asp or Gly"
- 50 (ix) FEATURE:  
(A) NAME/KEY:  
(B) LOCATION: 154  
(D) OTHER INFORMATION: /note= "Xaa is Gly or Ala"
- 55 (ix) FEATURE:  
(A) NAME/KEY:  
(B) LOCATION: 187  
(D) OTHER INFORMATION: /note= "Xaa is Ile or Thr"
- 60 (ix) FEATURE:  
(A) NAME/KEY:  
(B) LOCATION: 223  
(D) OTHER INFORMATION: /note= "Xaa is Val or Phe"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

5	Ile 1	Ala	Lys	Val 5	Pro	Gly	Pro	Asn	Ile 10	Thr	Ala	Glu	Tyr	Gly 15	Asp
	Lys	Trp	Leu 20	Asp	Ala	Lys	Ser	Thr 25	Trp	Tyr	Gly	Lys	Pro	Thr 30	Gly Ala
10	Gly	Pro	Lys 35	Asp	Asn	Gly	Gly	Ala 40	Cys	Gly	Tyr	Lys	Xaa 45	Val	Asp Lys
	Ala	Pro	Phe 50	Asn	Gly	Met 55	Thr	Gly	Cys	Gly	Asn 60	Thr	Pro	Ile	Phe Lys
15	Asp 65	Gly	Arg	Gly	Cys 70	Gly	Ser	Cys	Phe	Glu 75	Ile	Lys	Cys	Thr	Lys Pro 80
	Glu	Ser	Cys	Ser 85	Gly	Glu	Ala	Val	Thr 90	Val	Thr	Ile	Thr	Asp 95	Asp Asn
20	Glu	Glu	Pro	Ile 100	Ala	Pro	Tyr	His	Phe 105	Asp	Leu	Ser	Gly	His 110	Ala Phe
25	Gly	Ser	Met 115	Ala	Lys	Lys	Gly	Glu 120	Glu	Gln	Lys	Leu	Arg 125	Ser	Ala Gly
	Glu	Leu	Glu 130	Leu	Gln	Phe	Arg 135	Arg	Val	Lys	Cys	Lys 140	Tyr	Pro	Asp Xaa
30	Thr 145	Lys	Pro	Thr	Phe 150	His	Val	Glu	Lys	Xaa 155	Ser	Asn	Pro	Asn	Tyr Leu 160
<hr/>															
35	Ala	Ile	Leu	Val 165	Lys	Tyr	Val	Asp	Gly 170	Asp	Gly	Asp	Val	Val	Ala Val 175
	Asp	Ile	Lys 180	Glu	Lys	Gly	Lys	Asp	Lys 185	Trp	Xaa	Glu	Leu	Lys 190	Glu Ser
40	Trp	Gly	Ala 195	Val	Trp	Arg	Ile	Asp 200	Thr	Pro	Asp	Lys	Leu 205	Thr	Gly Pro
	Phe	Thr 210	Val	Arg	Tyr	Thr 215	Thr	Glu	Gly	Gly	Thr 220	Lys	Ser	Glu	Xaa Glu
45	Asp 225	Val	Ile	Pro	Glu 230	Gly	Trp	Lys	Ala	Asp 235	Thr	Ser	Tyr	Ser	Ala Lys 240

50 (2) INFORMATION FOR SEQ ID NO:58:

(1) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 240 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

60 (v) FRAGMENT TYPE: internal

(ix) FEATURE:  
(A) NAME/KEY:

(B) LOCATION: 199

(D) OTHER INFORMATION: /note= "Xaa is Val or Ile"

## (ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION: 235

(D) OTHER INFORMATION: /note= "Xaa is Ala or Thr"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

5  
 10 Ile Pro Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 10 15  
 15 Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala  
 20 25 30  
 Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45  
 20 Ala Pro Phe Asn Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60  
 Asp Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80  
 25 Glu Ser Cys Ser Gly Glu Ala Val Thr Val His Ile Thr Asp Asp Asn  
 85 90 95  
 30 Glu Glu Pro Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe  
 100 105 110  
 Gly Ser Met Ala Lys Lys Gly Glu Glu Gln Lys Leu Arg Ser Ala Gly  
 115 120 125

Glu Leu Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Glu Gly  
 130 135 140  
 5 Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu  
 145 150 155 160  
 Ala Leu Leu Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val  
 165 170 175  
 10 Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Ala Leu Lys Glu Ser  
 180 185 190  
 Trp Gly Ala Ile Trp Arg Xaa Asp Thr Pro Asp Lys Leu Thr Gly Pro  
 195 200 205  
 15 Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ser Glu Val Glu  
 210 215 220  
 20 Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Xaa Ser Tyr Glu Ser Lys  
 225 230 235 240

## (2) INFORMATION FOR SEQ ID NO:59:

25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 240 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 10 15  
 40 Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala  
 20 25 30  
 45 Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45  
 Pro Pro Phe Ser Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60  
 50 Ser Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80  
 Glu Ala Cys Ser Gly Glu Pro Val Val Val His Ile Thr Asp Asp Asn  
 85 90 95  
 55 Glu Glu Pro Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe  
 100 105 110  
 60 Gly Ala Met Ala Lys Lys Gly Asp Glu Gln Lys Leu Arg Thr Ala Gly  
 115 120 125  
 Glu Leu Glu Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Glu Gly  
 130 135 140

2157596

Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu  
 145 150 155 160  
 Ala Leu Leu Val Lys Tyr Val Asn Gly Asp Gly Asp Val Val Ala Val  
 165 170 175  
 Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser  
 180 185 190  
 Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro  
 195 200 205  
 Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Thr Glu Ala Glu  
 210 215 220  
 Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser Tyr Glu Ser Lys  
 225 230 235 240

(2) INFORMATION FOR SEQ ID NO:60:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 240 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear  
 (ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal

(ix) FEATURE:  
 (A) NAME/KEY:  
 (B) LOCATION: 88  
 (D) OTHER INFORMATION: /note= "Xaa is Val or Ile"

(ix) FEATURE:  
 (A) NAME/KEY:  
 (B) LOCATION: 90  
 (D) OTHER INFORMATION: /note= "Xaa is Val or Ile"

(ix) FEATURE:  
 (A) NAME/KEY:  
 (B) LOCATION: 180  
 (D) OTHER INFORMATION: /note= "Xaa is Gln or Glu"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:  
 Ile Ala Lys Val Pro Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Asp  
 1 5 10 15  
 Lys Trp Leu Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Xaa  
 20 25 30  
 Gly Pro Lys Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys  
 35 40 45  
 Pro Pro Phe Ser Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys  
 50 55 60  
 Ser Gly Arg Gly Cys Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro  
 65 70 75 80  
 Glu Ser Cys Ser Gly Glu Pro Xaa Leu Xaa His Ile Thr Asp Asp Asn

85 90 95

Glu Glu Pro Ile Ala Ala Tyr His Phe Asp Leu Ser Gly Lys Ala Phe  
100 105 110

5 Gly Ala Met Ala Lys Lys Gly Glu Glu Gln Lys Leu Arg Ser Ala Gly  
115 120 125

10 Glu Leu Glu Leu Lys Phe Arg Arg Val Lys Cys Glu Tyr Pro Lys Gly  
130 135 140

Thr Lys Val Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu  
145 150 155 160

15 Ala Leu Leu Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val  
165 170 175

Asp Ile Lys Xaa Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser  
180 185 190

20 Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro  
195 200 205

25 Phe Thr Val Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ala Glu Ala Glu  
210 215 220

Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ala Tyr Glu Ala Lys  
225 230 235 240

## 30 (2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal

40

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

45 Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Leu Leu Val Lys Tyr  
1 5 10 15

Val Asp Gly Asp  
20

50

## (2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal

60

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

2157596

Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Leu Leu Val Lys Tyr  
 1 5 10 15

5 Val Asn Gly Asp  
 20

(2) INFORMATION FOR SEQ ID NO:63:

10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Gly Asp Val Val Ala Val Asp Ile Lys Glu Lys Gly Lys Asp Lys Trp  
 1 5 10 15

25 Ile Ala Leu Lys  
 20

(2) INFORMATION FOR SEQ ID NO:64:

30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Gly Asp Val Val Ala Val Asp Ile Lys Gln Lys Gly Lys Asp Lys Trp  
 1 5 10 15

45

Ile Glu Leu Lys  
 20

50 (2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: peptide  
 (v) FRAGMENT TYPE: internal

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:



2157596

Glu Ser Trp Gly Ala Ile Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr  
 1 5 10 15

Gly Pro Phe Thr  
 20

5

## (2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: peptide

15

(v) FRAGMENT TYPE: internal

20

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Glu Ser Trp Gly Ala Ile Trp Arg Val Asp Thr Pro Asp Lys Leu Thr  
 1 5 10 15

25

Gly Pro Phe Thr  
 20

## (2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

30

35

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

40

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Thr Glu Ala Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser  
 1 5 10 15

45

Tyr Glu Ser Lys  
 20

## (2) INFORMATION FOR SEQ ID NO:68:

50

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

60

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Ala Glu Ala Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ala

2157596

1 5 10 15

Tyr Glu Ala Lys  
20

5 (2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:  
10 (A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

20 Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Ala Ser  
1 5 10 15

Tyr Glu Ser Lys  
20

25 (2) INFORMATION FOR SEQ ID NO:70:

(i) SEQUENCE CHARACTERISTICS:  
30 (A) LENGTH: 20 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

35 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

40 Ser Glu Val Glu Asp Val Ile Pro Glu Gly Trp Lys Ala Asp Thr Ser  
1 5 10 15

45 Tyr Glu Ser Lys  
20

(2) INFORMATION FOR SEQ ID NO:71:

50 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

60 GGGTCTAGAG GTACCGTCCG ATCGATCATT  
30

2157596

## (2) INFORMATION FOR SEQ ID NO:72:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

AATGATCGAT GCT  
13

## (2) INFORMATION FOR SEQ ID NO:73:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

GCGTCTAGAG GTACCGTCCG  
20

## (2) INFORMATION FOR SEQ ID NO:74:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

CCCTGCAGAT TATTGAGAT CTTGAG  
26

## (2) INFORMATION FOR SEQ ID NO:75:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 29 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CCCTGCAGTC ATGCTCACTT GGCCGAGTA  
29

5 (2) INFORMATION FOR SEQ ID NO:76:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
10 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

GAGTACGGCG ACAAGTGGC  
20 19

(2) INFORMATION FOR SEQ ID NO:77:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
25 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: cDNA

---

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

35 TTCGAGATCA AGTGCACC  
18

40 (2) INFORMATION FOR SEQ ID NO:78:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 base pairs  
(B) TYPE: nucleic acid  
45 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

50

2157596

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

GTGACAGCCT CGCCGG  
16

5

(2) INFORMATION FOR SEQ ID NO:79:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: cDNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

GGGAATTCCA TGGCGAAGAA GGGC  
24

20

(2) INFORMATION FOR SEQ ID NO:80:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

30

(ii) MOLECULE TYPE: cDNA

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GTGCCGTCCG GGTACT  
16

40 (2) INFORMATION FOR SEQ ID NO:81:

(1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: cDNA

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

CCGTCGACGT ACTTCA  
16

55

## (2) INFORMATION FOR SEQ ID NO:82:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

GGAGTCGTGG GGAGCAGTC  
19

## (2) INFORMATION FOR SEQ ID NO:83:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

GGGTCTAGAG GTACCGTCC  
19

## (2) INFORMATION FOR SEQ ID NO:84:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

TTGGATCCTA CGGCAAGCCG ACCGGC  
26

## (2) INFORMATION FOR SEQ ID NO:85:

- (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 28 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

2157596

TTGGATCCAT CCCGAAGGTG CCCCCGGG  
28

5 (2) INFORMATION FOR SEQ ID NO:86:

- 10 (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

20 AGGTGACCTT CCACGTCG  
18

(2) INFORMATION FOR SEQ ID NO:87:

- 25 (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: cDNA

---

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

35 TTGGATCCTG GCGCTGCTGG TGAAGTA  
27

(2) INFORMATION FOR SEQ ID NO:88:

- 40 (1) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
45 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

50

2157596

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:  
TTGAATTCAT CCCGAAGGTG CCCCCG  
26

5 (2) INFORMATION FOR SEQ ID NO:89:

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:  
TTGGTACCTC ACTTGGACTC GTAGCT  
26

20 (2) INFORMATION FOR SEQ ID NO:90:

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 25 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: cDNA

---

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:  
CCGAATTCGT GGAGAAGGGG TCCAA  
25

40 (2) INFORMATION FOR SEQ ID NO:91:

45 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 22  
55 (D) OTHER INFORMATION: /note= "Xaa is Iosine"



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

TTAGGATCCT CACTTATCAT ANGACGTATC  
30

5

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 25 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: cDNA

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

TTGAATTCCT TGTCATTGCC CTTCTG  
26

20

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

30

(ii) MOLECULE TYPE: cDNA

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

AAGAATTCCT TCTGCTTGAT GTCCAC  
26

40

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: cDNA

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

ATGAATTCGA GTCGTGGGGA GCCGTC  
26

55

2157596

## (2) INFORMATION FOR SEQ ID NO:95:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

ATGAATTCGT CTGGAGGATC GACACC  
26

## (2) INFORMATION FOR SEQ ID NO:96:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

ATGAATTCAT CGCAAAGGTT CCCCCC  
26

## (2) INFORMATION FOR SEQ ID NO:97:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

TTTGGATCCT CACTTGGACT CGTAGCT  
27

## (2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 25 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

WO 94/21675

2157596

PCT/US94/02537

TTGAATTCTC GCGAAGGTGC CCCCCG  
25

2157596

51	CAAATTC AAG ACAAG ATG GCG TCC TCC TCG GTG CTC CTG GTG GTG GCG	
	Met Ala Ser Ser Ser Val Leu Leu Val Val Ala	
	-23 -20 -15	
99	CTG TTC GCC GTG TTC CTG GGC AGC GCG CAT GGC ATC GCG AAG GTA CCA	
	Leu Phe Ala Val Phe Leu Gly Ser Ala His Gly Ile Ala Lys Val Pro	5
	-10 -5 1	
147	CCG GGC CCC AAC ATC ACG GCC GAG TAC GGC GAC AAG TGG CTG GAC GCG	
	Pro Gly Pro Asn Ile Thr Ala Glu Tyr Gly Asp Lys Trp Leu Asp Ala	20
	10 15	
195	AAG AGC ACC TGG TAT GGC AAG CCG ACC GGC GCC GGT CCC AAG GAC AAC	
	Lys Ser Thr Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp Asn	35
	25 30	
243	GGC GGC GCG TGC GGG TAC AAG GAC GTT GAC AAG GCG CCG TTC AAC GGC	
	Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys Ala Pro Phe Asn Gly	50
	40 45	
291	ATG ACC GGC TGC GGC AAC ACC CCC ATC TTC AAG GAC GGC CGT GGC TGC	
	Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys Asp Gly Arg Gly Cys	65
	55 60	
339	GGC TCC TGC TTC GAG ATC AAG TGC ACC AAG CCC GAG TCC TGC TCC GGC	
	Gly Ser Cys Phe Glu Ile Lys Cys Thr Lys Pro Glu Ser Cys Ser Gly	85
	70 75 80	

Fig. 1

2157596

GAG GCT GTC ACC GTC ACA ATC ACC GAC GAC	AAC GAG GAG CCC ATC GCA	387
Glu Ala Val Thr Val Thr 90	Asn Glu Glu Pro Ile Ala 100	
CCC TAC CAT TTC GAC CTC TCG GGC CAC GCG	TTC GGG TCC ATG GCG AAG	435
Pro Tyr His Phe Asp Leu Ser Gly His Ala 110	Phe Gly Ser Met Ala Lys 115	
AAG GGC GAG GAG CAG AAG CTC CGC AGC GCC	GGC GAG CTG GAG CTC CAG	483
Lys Gly Glu Glu Gln Lys Leu Arg Ser Ala 125	Gly Glu Leu Glu Leu Gln 130	
TTC AGG CGG GTC AAG TGC AAG TAC CCG GAC	GGC ACC AAG CCG ACA TTC	531
Phe Arg Arg Val Lys Cys Lys Tyr Pro Asp 140	Gly Thr Lys Pro Thr Phe 145	
CAC GTC GAG AAG GCT TCC AAC CCC AAC TAG	CTC GCT ATT CTG GTG AAG	579
His Val Glu Lys Ala Ser Asn Pro Asn Tyr 155	Leu Ala Ile Leu Val Lys 160	
TAC GTC GAC GGC GAC GGT GAC GTG GTG GCG	GTG GAC ATC AAG GAG AAG	627
Tyr Val Asp Gly Asp Gly Asp Val Val Ala 170	Val Asp Ile Lys Glu Lys 180	

Fig. 1 cont.

2157506

GGC AAG GAT AAG TGG ATC GAG CTC GAG TCG TGG	GGA GCA GTC TGG	675
Gly Lys Asp Lys Trp 185	Gly Ala Val Trp	
	195	
AGG ATC GAC ACC CCC GAT AAG CTG ACG GGC CCA TTC	ACC GTC CGC TAC	723
Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro Phe	Thr Val Arg Tyr	
	210	
ACC ACC GAG GGC ACC ACC AAA TCC GAA GTC GAG GAT	GTC ATC CCT GAG	771
Thr Thr Glu Gly Thr Gly Thr Lys Ser Glu Val Glu Asp	Val Ile Pro Glu	
	195	
	220	
GGC TGG AAG GCC GAC ACC TCC TAC TCG GCC AAG TGAGCA		810
Gly Trp Lys Ala Asp 235		
	240	
	230	

Fig. 1 cont.

2157596

## PEPTIDE NAME

## PEPTIDE SEQUENCE

LPI-1

IAKVPPGPNITA EYGDKWLD

LPI-1.1

IAKVXPGXNITA EYGDKWLD

LPI-2

TAEYGDKWLD AKSTWYGKPT

LPI-3

AKSTWYGKPTGAGPKDNGGA

LPI-4

GAGPKDNGGACGYKNVDKAP

LPI-4.1

GAGPKDNGGACGYKDVDKAP

LPI-5

CGYKDVDKAPFNGMTGCGNT

LPI-6

FNGMTGCGNTPIFKDGRGCG

LPI-7

PIFKDGRGCGSCFEIKCTKP

LPI-8

SCFEIKCTKPESCSGEAVTV

LPI-9

ESCSGEAVTVTITDDNEEPI

LPI-10

TITDDNEEPIAPYHFDLSGH

LPI-11

APYHFDLSGHAFGSMADDGE

LPI-11.1

APYHFDLSGHAFGSMAKKGE

LPI-12

AFGSMADDGEEQKLRSAGEL

LPI-12.1

AFGSMAKKGEEQKLRSAGEL

LPI-13

EQKLRSAGELELQFRRVKCK

LPI-14

ELQFRRVKCKYPDDTKPTFH

LPI-15

YPDDTKPTFHVEKASNPNYL

LPI-16

VEKASNPNYLAILVKYVDGD

LPI-16.1

VEKASNPNYLAILVKYVDGD

LPI-17

AILVKYVDGDGDVVAVDIKE

LPI-18

GDVVAVDIKEKGKDKWIELK

LPI-19

KGKDKWIELKESWGAVWRID

LPI-20

ESWGAVWRIDTPDKLTGPFT

LPI-21

TPDKLTGPFTVRYTTEGGTK

LPI-22

VRYTTEGGTKSEVEDVIPEG

LPI-23

SEVEDVIPEGWKADTSYS AK

Fig. 2

2157596




Fig. 3



2157596

PEPTIDE NAME	PEPTIDE SEQUENCE
LPI-16.1	VEKGSNPNYLAILVKYVDGD
LPI-16.2	DEVEKGSNPNYLAILVKYVDGD
LPI-16.3	DEAEKGSNPNYLAILVKYVDGD
LPI-16.4	KKVEKGSNPNYLAILVKK
LPI-16.5	VEKGSNPNYLAIIDE
LPI-16.6	AEKGSNPNYLAIIDE
LPI-16.7	DEVEKGSNPNYLAIDE
LPI-16.9	KKAEKGSNPNYLAILVKK
LPI-16.10	DEPNYLAILVKYVDE
LPI-18	GDVVAVDIKEKGKDKWIELK
LPI-18.5	GDVVAVDIKEKGKDK
LPI-18.6	VAVDIKEKGKDKWIE
LPI-18.7	AVDIKEKGKDKWIEL
LPI-18.8	DIKEKGKDKWIELK
LPI-20	ESWGAVWRIDTPDKLTGPFT
LPI-20.2	WGAVWRIDTPDKLT
LPI-20.3	GAVWRIDTPDKLTG
LPI-20.4	WRIDTPDKLTGPFT
LPI-20.5	ESWGAVWRIDTPDK
LPI-20.6	AGAVWRIDTPDKLT
LPI-23	SEVEDVIPEGWKADTSYSK
LPI-23.1	SEVEDVIPEGWKADT
LPI-23.2	EDVIPEGWKADTSYS
LPI-23.4	IPEGWKADTSYSK

Fig. 4

2157596

ATCCGGAAGGTGCCCCCGGGCCCGAACAATCACGGCGGACCTACGGTGACAAAGTGGCTGGAC 60  
I P K V P P P G P N I T A T Y G D K W L D 20  
1 10

GCGAAGAGCACATGTTACGGCAAGCCGACGGCGCGGCCCCCAAGGACAACGGCGGCGCG 120  
A K S T W Y G K P T G A G P K D N G G A 40  
30

TGCGGGTACAAGGACGTGGACAAGCGCCGTTCAACGGCATGACCGGGTGCGGCAACACC 180  
C G Y K D V D K A P F N G M T G C G N T 60  
50

CCCATCTTCAAGGACGGGGCGGGTGCGGTTCCTGCTTCGAGATCAAGTGCACGAAGCCC 240  
P I F K D G R G C G S C F E I K C T K P 80  
70

GAGTCGTGCTCCGGCGAGGCCGTCAACCGTCCACATCACCGACGACAACGAGGAGCCCATC 300  
E S C S G E A V T V H I T D D N E E P I 100  
90

GCGCCCTACCACTTCGACCTTTCGGGCCACGGTTCGGTTCATGGCGAAGAAGGCGGAG 360  
A P Y H F D L S G H A F G S M A K K G E 120  
110

GAGCAGAAGCTGCGCAGCGGGCGGAGCTGGAGCTGCAGTTAGCGGGTGAAGTGCAAG 420  
E Q K L R S A G E L E L Q F R R V K C K 140  
130

Fig. 5

2157596

TACCCCGAGGGCACCAAGGTGACCTTCCACGTCGAGAAGGGTTCCAACCCCAACTACCTG 480  
Y P E G T K V T F H V E K G S N P N Y L 160  
150

GGCTGCTGGTGAAGTACGTCGACGGCGGACGGCGGAGTGGTGGCGGTGATATCAAGGAG 540  
A L L V K Y V D G D G D V V A V D I K E 180  
170

AAGGCAAGGACAAGTGGATCGCGCTCAAGGAGTCAATGGGAGCCATCTGGAGGGTGGAC 600  
K G K D K W I A L K E S W G A I W R V D 200  
190

ACCCCGACAAGCTGACGGGCCCATTCACCGTTCGCTACACCCGAGGGAGGCACCAAG 660  
T P D K L T G P F F T V R Y T T E G G T K 220  
210

TCCGAAGTTGAGGACGTCATCCCCGAGGGCTGGAAGGCCGACGCCAGCTACGAGTCCAAG 720  
S E V E D V I P E G W K A D A S Y E S K 240  
230

TGA 723

Fig. 5 cont.

2157596

ATCGCGAAGTTCCCCCGGCCGAACATCAGCGGACCTACGGCGACAAGTGGCTTGAC 60  
I A K V P P G P N I T A T Y G D K W L D 20  
1 10

GCGAAGAGCACCTGGTACGGCAAGCCGACCGGNBCCGGTCCCAAGGACAACGGCGGCGCG 120  
A K S T W Y G K P T G X G P K D N G G A 40  
30

TGCGGATACAAGGACGTGGACAAGCCCCCGTTACGGGCGATGACCGGCTGCGGCAACACC 180  
C G Y K D V D K P P F S G M T G C G N T 60  
50

CCCATCTTCAAGTCCGGCCCGGCTGCGGCTCCTGCTTCGAGATCAAGTGCACCAAGCCC 240  
P I F K S G R G C G S C F E I K C T K P 80  
70

GAGTCCTGCTCCGGGGAGCCCGTCTGGTCCACATCACCGACGACAACGAGGAGCCCATC 300  
E S C S G E P V L V H I T D D N E E P I 100  
90

GCCGCCCTACCACTTCGACCTCTCCGGCAAGCGGTTCCGGGGCCATGGCCAAGAAGGTGAG 360  
A A Y H F D L S G K A F G A M A K K G E 120  
110

Fig. 6

2157596

GAGCAGAAGCTGCGCAGCGCGCGGAGCTGGAGCTCAAGTTCCGCCGCGTCAAGTGCGGAG 420  
E Q K L R S A G E L E L K F R R V K C E 140  
130

TACCCGAAGGCAACCAAGGTACCTTCCACGTCGAGAAGGGGTCCAAACCCCACTACCTT 480  
Y P K G T K V T F H V E K G S N P N Y L 160  
150

GCGCTGCTGGTGAAGTACGTCGACGGCGGACGGGGACGTGGTGGCGGTGGACATCAAGCAG 540  
A L L V K Y V D G D G D V V A V D I K Q 180  
170

AAGGGCAAGGACAAGTGGATCGAGCTCAAGGAGTCGTGGGGAGCCGTCCTGGAGGATCGAC 600  
K G K D K W I E L K E S W G A V W R I D 200  
190

ACCCCGACAAGCTACCGGGCCCTTCACCGTCCGCTACACCAAGGGCGGCACCAAG 660  
T P D K L T G P F T V R Y T T E G G T K 220  
210

GCCGAAGCCGAGGACGTATCCCCGAGGGCTGGAAGGCCGACACCGCCTACGAGGCCAAG 720  
A E A E D V I P E G W K A D T A Y E A K 240  
230

TGA 723

Fig. 6 cont.

2157596

ATCGGAAGGTGCCCCGGGTCCGAACATCACGGCGACCTACGGCGACAAGTGGCTCGAC 60  
I A K V P P P N I T A T Y G D K W L D 20  
1 10

GCGAAGAGCACATGGTACGGCAAGCCGACGGGGCCGGTCCCAAGGACAACGGCGGCGCT 120  
A K S T W Y G K P T G A G P K D N G G A 40  
30

TGCGGGTACAAGGACGTGGACAAGCCCCCGTTCAGCGGCATGACCGGCTGCGGCAACACC 180  
C G Y K D V D K P P F S G M T G C G N T 60  
50

CCCATCTCAAGTCCGGCCGTGGCTGCGGCTCCCTGCTTTGAGATCAAGTGCACGAAGCCC 240  
P I F K S G R G C G S C F E I K C T K P 80  
70

GAGGCCTGCTCCGGCGAGCCCGTGGTAGTCCACATCACCGACGACAACGAGGAGCCCATC 300  
E A C S G E P V V H I T D D N E E P I 100  
90

GCCCCCTACCACTTCGACCTCTCCGGCCACGCGTTCGGGGCGATGGCCAAGAAGGCGGAT 360  
A P Y H F D L S G H A F G A M A K K G D 120  
110

Fig. 7

2157596

GAGCAGAAGCTGCGCACGGCCGGCGAGCTGGAGCTCCAGTTCCGGCGGTCAAGTGCAAG 420  
E Q K L R T A G E L E L Q F R R V K C K 140  
130

TACCCGGAGGGACCAAGGTGACCTTCCACGTGGAGAAGGGTCCAACCCCACTACCTG 480  
Y P E G T K V T F H V E K G S N P N Y L 160  
150

GCGTGTCTGTGAAGTACGTTACGGCGGACGAGACGTGGTGGCGGTGGACATCAAGGAG 540  
A L L V K Y V N G D G D V V A V D I K E 180  
170

AAGGCAAGGACAAGTGGATCGAGCTCAAGGAGTCGTGGGGAGCCATCTGGAGGATCGAC 600  
K G K D K W I E L K E S W G A I W R I D 200  
190

ACTCCCGACAAGCTCAGGGCCCCCTTCACCGTCCGCTACACCAAGGGGGCGGCACCAAG 660  
T P D K L T G P F T V R Y T T E G G T K 220  
210

ACCGAAGCCGAGGACGTCATCCCTGAGGGCTGGAAGGCCGACACCAAGCTACGAGTCCAAG 720  
T E A E D V I P E G W K A D T S Y E S K 240  
230

TGA 723

Fig. 7 cont.

2157596

1	10	20	30	40	50	60	
IAKVP	PGPNITAEY	GDKWLD	DAKSTWY	GKPTGAG	PKDNGGAC	GK <sup>D</sup> <sub>N</sub> VDKAPFNGMTGCGNT	Lol p I
-P	-T	-T	-T	-T	-D	-D	Dac g I
-T	-T	-T	-T	-T	-D	-D	Phl p I
-T	-T	-T	-T	-T	-D	-D	Poa p I
70	80	90	100	110	120		
PIFKD	GRGSGCFEIK	TKPESCSGE	AVT <sup>D</sup> VTITDDNEE	PIAPHFDLS	GHAFGSM	AKKGE	Lol p I
-S	-S	-S	-S	-S	-S	-S	Dac g I
-S	-S	-S	-S	-S	-S	-S	Phl p I
							Poa p I
130	140	150	160	170	180		
EQKLS	AGELELQFRR	VCKY <sup>D</sup> PD <sup>G</sup> TKPTF	HFVEK <sup>G</sup> <sub>A</sub> SNPNYL	AILVKY	VDGDGDV	VAVDIKE	Lol p I
-T	-T	-T	-T	-T	-T	-T	Dac g I
-T	-T	-T	-T	-T	-T	-T	Phl p I
-K	-K	-K	-K	-K	-K	-K	Poa p I
190	200	210	220	230	240		
KGKDKW <sup>I</sup>	ELKESWGAV	WRIDTPDKL	TGPFTVRYTTE	GK <sup>F</sup> SE <sup>V</sup>	VEDVI	PEGWKADTSYSAK	Lol p I
-IA	-IA	-IA	-IA	-IA	-IA	-IA	Dac g I
-I	-I	-I	-I	-I	-I	-I	Phl p I
-I	-I	-I	-I	-I	-I	-I	Poa p I

Fig. 8



2157596

PEPTIDE NAME	PEPTIDE SEQUENCE
LPI-16.1	VEKGSNPNYLAILVKYVDGD
LPI-16.8	VEKGSNPNYLAILVKYVDGD
LPI-16.N	VEKGSNPNYLAILVKYVNGD
LPI-18	GDVVAVDIKEKGKDKWIELK
LPI-18.9	GDVVAVDIKEKGKDKWIALK
LPI-18.X	GDVVAVDIKQKGKDKWIELK
LPI-20	ESWGAVWRIDTPDKLTGPFT
LPI-20.7	ESWGAIWRIDTPDKLTGPFT
LPI-20.Y	ESWGAIWRVDTPDKLTGPFT
LPI-23	SEVEDVIPEGWKADTSYSK
LPI-23.5	TEAEDVIPEGWKADTSYESK
LPI-23.6	AEAEDVIPEGWKADTAYEAK
LPI-23.Z	SEVEDVIPEGWKADASYESK
LPI-23.ZZ	SEVEDVIPEGWKADTSYESK

Fig. 9